

## **Cumulative Index 1981-1983**

### **SYMPOSIA**

---

#### **1981**

*March* TECHNOLOGY ASSESSMENT  
*June* PERINATAL DIAGNOSIS  
*September* THERAPEUTIC DRUG MONITORING  
*December* LABORATORY ASSESSMENT OF NUTRITIONAL STATUS

#### **1982**

*March* BLOOD BANKING AND HEMOTHERAPY  
*June* RESPIRATORY INFECTIONS  
*September* LABORATORY MEASUREMENTS IN MALIGNANT DISEASE  
*December* TEST SELECTION STRATEGIES

#### **1983**

*March* COMPUTERS IN THE CLINICAL LABORATORY  
*June* FORENSIC PATHOLOGY  
*September* LABORATORY MANAGEMENT  
*December* TISSUE IMMUNOPATHOLOGY

---

*Note:* The volume year is in *italic type*.  
Page numbers of symposium and article titles are in **boldface type**.

ABO hemolytic disease, in neonate, *1981*:  
    *June*, 246-247  
exchange transfusion in, *1981*: *June*,  
    267-268  
ABO incompatibility, crossmatch and, *1982*:  
    *March*, 190  
in hemolytic disease of newborn, *1982*:  
    *March*, 110-116  
transfusion reactions and, *1982*: *March*,  
    229-230

ABO matching, in emergency cardiovascular  
    surgery, *1982*: *March*, 78-81  
ABO-Rh compatibility, in pretransfusion  
    testing, *1982*: *March*, 169-179  
ABO-Rh typing, in autoimmune hemolytic  
    anemia, *1982*: *March*, 195-198  
ABO system, *1982*: *March*, 141  
ABO typing, in emergency transfusion,  
    *1982*: *March*, 78-81  
Abuse. See *Child abuse*.

Accident(s), drug use and, 1983: June, 306, 379-380  
 hit-and-run, collection of evidence in, 1983: June, 357, 364

Accident reports, 1983: Sept., 476

Accuracy, in quality control studies, 1983: Sept., 548

Acetaminophen, perinatal effects, 1981: June, 368  
 therapeutic monitoring of, 1981: Sept., 573-578  
 toxic effects, 1981: Sept., 575-577

Acetylsalicylic acid, effect on inflammatory response, 1983: Dec., 706  
 therapeutic monitoring of, 1981: Sept., 567-573

Acid(s), essential fatty, deficiency, 1981: Dec., 666  
 laboratory assessment of, 1981: Dec., 618, 665-672

Acid-fast stain(s), in tuberculosis, 1982: June, 311-312

Acidosis, fetal, monitoring of, 1981: June, 215-225

Acrodermatitis enteropathica, zinc status and, 1981: Dec., 747

Adult respiratory distress syndrome. See *Respiratory distress syndrome, adult*.

Affective disorders, drug therapy for, 1981: Sept., 541-545

Age, chlamydial respiratory infection and, 1982: June, 372-375

Agglutination of red blood cells, 1982: March, 155-167

Agglutination tests, in antigen detection, 1981: March, 55-56

Albumin, as nutritional index, 1981: Dec., 770  
 dye-binding procedures, 1981: June, 333-336  
 erythrocyte agglutination and, 1982: March, 165-166  
 fluid therapy and, 1982: March, 50-52  
 in neonatal transfusion, 1981: June, 297  
 reserve, estimation of binding capacity, 1981: June, 329-343

Alcohol, beverage, defined, 1983: June, 385-386  
 effect on CEA clearance, 1982: Sept., 459-467  
 ethyl, blood levels of, 1983: June, 383  
 in fire victims, 1983: June, 306  
 metabolism of, 1983: June, 388-389  
 poisoning by, 1983: June, 385-396  
 therapeutic monitoring of, 1981: Sept., 581-583  
 iron status and, 1981: Dec., 732  
 perinatal effect of, 1981: June, 368

Alcohol intoxication, 1981: Sept., 581-582

Alcoholism, laboratory diagnosis, 1981: Sept., 582

Aldosteronism, primary, test selection in, 1982: Dec., 795-796

Alkalemia, neonatal, 1981: June, 235

Allergic reaction(s). See *Anaphylaxis*.

Alloantibody(ies), detection, in autoimmune hemolytic anemia, 1982: March, 199-203  
 removal, by plasma exchange, 1982: March, 94-95

Alloimmunization, in transfusion therapy, 1981: March, 70, 72

Allograft, rejection, mechanisms of, 1983: Dec., 764-765

Alpha-fetoprotein, in diagnosis of neural tube defects, 1981: June, 181-188  
 in germ cell tumors, 1982: Sept., 435-440

Alpha-1,4-glucosidase deficiency, neonatal, 1981: June, 427

American Association of Blood Banks, 1983: Sept., 448

Aminoglycoside(s), toxic effects, 1981: Sept., 592-593

Amritriptyline, therapeutic monitoring of, 1981: Sept., 541-544

Ammunition. See also *Bullets; Cartridges*. historical development of, 1983: June, 259-260, 274-277

Amniocentesis, in diagnosis of neural tube defects, 1981: June, 188-192  
 in measurement of bilirubin levels, 1981: June, 323-324

Amniotic fluid, alpha-fetoprotein levels in, defects and, neural tube defects and, 1981: June, 188-192  
 bilirubin levels in, 1981: June, 323-324  
 phospholipid levels in, respiratory distress syndrome and, 1981: June, 199-213

ANA. See *Antinuclear antibody*.

Anaerobe(s), isolation of, 1982: June, 297-298

Anaerobic bacteria, in pleuropulmonary infection, 1982: June, 285-303

Anaerobic culture, collection and handling of specimens for, 1983: Sept., 534

Anaerobic systems, in respiratory infection, 1982: June, 298

Anaphylaxis. See also *Inflammatory response*.  
 mediators of, 1983: Dec., 619-643

Anaphylatoxin. See *Complement*.

Anatomic pathology, computer information systems in, 1983: March, 133-147  
 laboratory, 1983: Sept., 477

Anderson's disease, neonatal, 1981: June, 428

Anemia, autoimmune hemolytic, neonatal, 1981: June, 258-259  
 transfusion in, 1982: March, 193-210  
 iron deficiency, laboratory evaluation of, 1982: Dec., 751-777  
 iron status and, 1981: Dec., 729-741

Angiotensin converting enzyme, in endotoxin-induced lung injury, 1983: Dec., 731

subcellular sites of, 1983: Dec., 581-583

Anisotropy, angular, in light scattering, 1981: March, 98-99

Ankylosing spondylitis, HLA-B27 antigen and, 1982: March, 130-131

Anthropometric measurement(s), in nutritional assessment, 1982: Dec., 606, 612-615

Antibody(ies). See also *Immunoglobulin(s)*.  
antiglobulin test and, 1982: March, 176, 186-191  
blood group of, 1982: March, 79  
cell destruction and, 1982: March, 211-219  
detection, by laboratory techniques, 1983: Dec., 757-760  
in *Pneumocystis* infection, 1982: June, 403-404  
monoclonal, as reagents, 1981: March, 99-105  
in autoimmune disorders, 1983: Dec., 759-760  
in organ transplantation, 1983: Dec., 777

Antibody marker(s), of connective tissue disease, 1983: Dec., 754-757  
of endocrine disease, 1983: Dec., 750-753  
of liver disease, 1983: Dec., 749-750  
of muscular disease, 1983: Dec., 753  
of skin disease, 1983: Dec., 753-754  
thyroid disease, 1983: Dec., 750-752

Antibody-mediated perinatal disease, 1981: June, 239-263

Antibody screening, 1982: March, 112-113  
in pretransfusion testing, 1982: March, 169-179, 181-192

Anticoagulant(s), in blood storage, 1982: March, 4-6, 22-25

Anti-D antigen, Rh immunization and, 1982: March, 111-113

Antidiuretic hormone deficiency, neonatal, 1981: June, 414-416

Antigen(s), blood group, in breast cancer, 1982: Sept., 545-546  
carcinoembryonic, in breast cancer, 1982: Sept., 550-555. See also *Carcinoembryonic antigen*.  
delayed hypersensitivity response and, in malnutrition, 1981: Dec., 633-638  
detection, by immunologic technique, 1981: March, 49-65  
erythrocyte, in autoimmune hemolytic anemia, 1982: March, 198-199  
high incidence types, 1982: March, 145-146  
HLA, 1982: March, 123-135  
disease associations and, 1982: March, 130-132; 1983: Dec., 747-748

Antigen(s) (*Continued*)  
Kell type, in hemolytic disease of newborn, 1982: March, 111  
low incidence types, 1982: March, 144-145  
matching, in renal transplantation, 1982: March, 125-129  
shared, 1982: March, 147-148  
tumor-specific, in breast cancer, 1982: Sept., 544  
viral cross-reactive, in breast cancer, 1982: Sept., 546-547

Antiglobulin test, direct vs. indirect, 1982: March, 199-200  
in crossmatch, 1982: March, 176, 186-191

Antimicrobial agent(s), in anaerobic respiratory infection, 1982: June, 300-301  
therapeutic monitoring of, 1981: Sept., 585-597  
toxic effects, 1981: Sept., 587-595

Antinuclear antibody test, fluorescent, in SLE, 1982: Dec., 881-884

Antithrombin III, in cancer patients, 1982: Sept., 607  
in hypertensive complications of pregnancy, 1982: Dec., 755-756

Arachidonic acid, metabolic pathways of, 1983: Dec., 623-624, 698  
metabolism, macrophage activation and, 1983: Dec., 677-694  
metabolites. See also specific substances, as *Prostaglandin(s)*; *Leukotriene(s)*.  
in endotoxin-induced lung injury, 1983: Dec., 724-729  
in inflammatory response, 1983: Dec., 684-685  
in neutrophil-mediated lung injury, 1983: Dec., 609-611

ARDS. See *Respiratory distress syndrome, adult*.

Ariboflavonosis, 1981: Dec., 688-690

Arrhythmia(s), drug therapy for, 1981: Sept., 501-522, 523-533

Arthritis. See also *Inflammatory disease(s)*.  
prostaglandins and, 1983: Dec., 704-706  
rheumatoid, antibody markers of, 1983: Dec., 754-757  
arachidonate metabolites and, 1983: Dec., 685-689

ARTHUR program, applications in test selection, 1982: Dec., 737, 741-742

Arthus reaction, prostaglandins and, 1983: Dec., 706

Ascorbic acid. See *Vitamin C*.

Asphyxiation, in electrical deaths, 1983: June, 348  
vs. sudden infant death, 1983: June, 338-342

Aspiration, anaerobic infection and, 1982: June, 287

**Aspiration (Continued)**

- percutaneous lung, in respiratory infection, 1982: June, 278-279
- tracheal, in anaerobic respiratory infection, 1982: June, 292-293
- in respiratory infection, 1982: June, 271-273

**Aspirin.** See *Acetylsalicylic acid*.

**Assay(s).** See under specific types.

**Asthma,** anaphylactic mediators and, 1983: Dec., 628

**Audit control,** of laboratory information system, 1983: March, 176

**Autocoid(s),** in anaphylaxis, 1983: Dec., 619-620

**Autoantibody(ies),** in autoimmune hemolytic anemia, 1982: March, 194-195

- removal, by plasma exchange, 1982: March, 92-94
- specificity, 1982: March, 203-205

**Autoimmune disorder(s),** associated HLA antigens and, 1983: Dec., 747-748

laboratory diagnosis of, 1983: Dec., 745-761

**Autoimmune hemolytic anemia,** transfusion in, 1982: March, 193-210

**Autoimmunity,** theories of development, 1983: Dec., 745-747

**Automation.** See *Computer information systems*.

**Automobile(s),** defective design, product liability and, 1983: June, 403

**Autopsy,** in electrical deaths, 1983: June, 348-349

- in explosion deaths, 1983: June, 317-318
- in fire deaths, 1983: June, 298-306
- in product liability deaths, 1983: June, 399-400
- toxicologic analysis in, 1983: June, 368-370, 392-395

**Avidin-biotin complex method,** in detection of autoantibodies, 1983: Dec., 758-759

**B CELL(S).** See *Lymphocyte(s)*.

**Backups,** for software, in laboratory information system, 1983: March, 171-172

**Bacteria, anaerobic,** in pleuropulmonary infection, 1982: June, 285-303

**Bacterial colonization,** laboratory diagnosis, 1981: Sept., 595-596

**Ballistics, wounds,** 1983: June, 260-261

**BASIC,** 1983: March, 4, 7. See also *Programming languages*.

**Battered child,** 1983: June, 321-342. See also *Child abuse*.

**Bayes' theorem,** 1982: Dec., 754

- in assessment of laboratory diagnostic technology, 1981: March, 11-12, 27-32

**Bayes' theorem (Continued)**

- in classification of data, 1982: Dec., 729
- in multiple testing, 1982: Dec., 875-876
- variations, 1982: Dec., 687-690

**Benefit-risk analysis,** in clinical decision making, 1981: March, 25-26

**Betamethasone,** intrauterine treatment, 1981: June, 363

**3-Beta-ol-dehydrogenase deficiency,** neonatal, 1981: June, 411

"Big-ticket" technology, assessment of, 1981: March, 7-8

**Bilirubin,** conjugated, measurement of, 1981: June, 324-325

free, detection of, 1981: June, 329-343

levels, in perinatal diagnosis, 1981: June, 269-272, 311-327

metabolism, 1981: June, 311-313

photodecomposition of, 1981: June, 364

standards, 1981: June, 321-323

total, measurement of, 1981: June, 315-324

**Bilirubin encephalopathy,** neonatal, exchange transfusion in, 1981: June, 271-272

**Biodynamic models,** in test selection, 1982: Dec., 701-715

**Biomedical products,** defective design, liability and, 1983: June, 403-404

**Biopsy,** lung, in *Pneumocystis* infection, 1982: June, 395-396

open lung, in respiratory infection, 1982: June, 279-280

transbronchial lung, in respiratory infection, 1982: June, 275-276

**Blast.** See *Bombing(s); Explosion(s)*.

**Blood,** alcohol levels, 1983: June, 386-395

- in fire victims, 1983: June, 306
- as evidence, collection of, 1983: June, 360-362

**cell(s).** See *Erythrocyte(s)* or *Leukocyte(s)*.

compatibility, in neonatal exchange transfusion, 1981: June, 276-277

cultures, preanalytic factors in, 1983: Sept., 532

drug levels, 1983: June, 369, 371, 380-383

fecal scalp, sampling of, 1981: June, 215-225

incompatibility, neonatal jaundice and, 1981: June, 314

in electrical injury, 1983: June, 346

**platelet(s).** See *Platelet(s)*.

**poisoning.** See *Septicemia*.

prenatal testing, for antibody, 1981: June, 252-253, 268

reconstituted, in neonatal exchange transfusion, 1981: June, 277

storage of, 1981: June, 275-276, 289

transfusion, in neonate, 1981: June, 265-283

Blood (*Continued*)  
whole. See *Whole blood*.

Blood bank(ing), automated systems in, 1983: March, 111-132  
current technology, 1981: March, 67-76  
inventory levels, 1982: March, 169-170  
symposium on, 1982: March, 3-252

Blood components, conservation, 1982:  
March, 69-72  
in hemotherapy, 1982: March, 3-19  
therapy, in neonatal intensive care, 1981:  
June, 285-309

transfusion, in cardiovascular surgery,  
1982: March, 75-82

Blood donor, screening, 1982: March, 243-  
245  
selection, 1982: March, 183-184  
in autoimmune hemolytic anemia, 1982:  
March, 205-207

Blood gas(es), collection and handling of  
specimens for, 1983: Sept., 525

Blood group(s), recent advances in, 1982:  
March, 137-154

Blood group antibodies, 1982: March, 79.  
See also *Antibody(ies)*.

Blood group antigen(s), in breast cancer,  
1982: Sept., 545-546

Blood group loci, chromosomal linkage of,  
1982: March, 137-141

Blood pressure, elevated. See *Hypertension*.

Blood products, federal regulation of, 1983:  
Sept., 444  
inventory management, 1981: March, 67-  
76  
labeling, in automated blood bank, 1983:  
March, 118-120, 123

Bloodstain, typing of, 1983: June, 360-362

Blood storage, 1982: March, 4-6, 22-25

Blood transfusion. See *Erythrocyte  
transfusion; Platelet transfusion;  
Transfusion*.

Blood typing, in pretransfusion testing,  
1982: March, 169-179. See also *ABO  
compatibility; ABO system; ABO  
typing; HLA antibodies*.

Blood volume, deficiency, fluid therapy in,  
1982: March, 55-56  
in neonate, 1981: June, 364-365

Blunt injury, in battered child, 1983: June,  
329-330

Bombing(s). See also *Explosion(s)*.  
explosive, injuries from, 1983: June, 304-  
305  
injuries from, 1983: June, 314-316

Bone, fracture. See *Fracture(s)*.  
resorption, prostaglandins and, 1983:  
Dec., 703  
tumors, hydroxyproline in, 1982: Sept.,  
537

Bone marrow, CK<sub>1</sub> activity in, 1982: Sept.,  
500

Bradykinin, in endotoxin-induced lung  
injury, 1983: Dec., 730-731

Brain injury, in battered child, 1983: June,  
333-334

Brancher deficiency, neonatal, 1981: June,  
428

Break-even analysis, in laboratory  
technology assessment, 1981: March,  
44-45

Breast, cancer, CK<sub>1</sub> activity in, 1982: Sept.,  
499  
hydroxyproline in, 1982: Sept., 523-528  
laboratory measurements in, assessment  
of, 1982: Sept., 657-678  
screening for, 1982: Sept., 646  
tumor markers for, 1982: Sept., 543-  
565

Breast milk, drugs excreted in, 1981: June,  
367

Bromcresol green, in albumin dye-binding,  
1981: June, 335

Bromphenol blue, in albumin dye-binding,  
1981: June, 335

Bromsulphalein test, hepatic function and,  
1982: Dec., 708-709

Bronchoalveolar lavage (BAL), in respiratory  
infection, 1982: June, 276-277

Bronchoscopy, in anaerobic respiratory  
infection, 1982: June, 293-294  
in respiratory infection, 1982: June, 273-  
275

Bruise(s), patterned, in battered child, 1983:  
June, 328-329

Bullet(s). See also *Cartridge(s)*.  
kinetic energy of, 1983: June, 260-261  
rifle, characteristics of, 1983: June, 261-  
264  
velocity of, effect on tissue injury, 1983:  
June, 278

Bullet wounds. See *Firearm wounds*.

Bupivacaine, perinatal effect of, 1981: June,  
368-369

Burn(s), electrical, 1983: June, 344-346  
extent of, estimation of, 1983: June, 301  
from explosions, 1983: June, 316  
in battered child, 1983: June, 330-332  
in bombing victims, 1983: June, 305  
in fire victims, 1983: June, 300-303  
inflammatory response in, 1983: Dec.,  
801-815

CAFFEINE in pregnancy, 1981: June 362,  
372

Calciferol. See *Vitamin D*.

Calcium, disorders, laboratory evaluation of,  
1982: Dec., 809-812  
in neutrophil stimulation, 1983: Dec.,  
781, 784-785

Calcium (*Continued*)  
 levels, effect of drugs on, 1981: Dec., 657-658  
 in neonate, 1981: June, 232-233  
 metabolism, in neonate, 1981: June, 229-232

Caliber, of firearm, 1983: June, 257-258  
 effect on tissue injury, 1983: June, 282-283

*Campylobacter fetus* infection, neonatal, 1981: June, 355

Cancer. See also under specific disease, as *Breast, cancer.*  
 CK<sub>1</sub> activity in, 1982: Sept., 493-506  
 collagen metabolites in, 1982: Sept., 519-542  
 detection, by mass screening, 1982: Sept., 627-638  
 by screening tests, 1982: Sept., 640  
 enzymatic activity in, 1982: Sept., 479-491  
 hemostatic abnormalities in, 1982: Sept., 599-625  
 laboratory measurements in, symposium on, 1982: Sept., 431-678  
 pancreatic, pancreas-specific antigen in, 1982: Sept., 567-578  
 test selection in, 1982: Dec., 876-878  
 polyamines in, 1982: Sept., 507-518  
 preclinical, detection of, 1982: Sept., 653-654  
 prostatic, test selection in, 1982: Dec., 692-695  
 screening tests, assessment of, 1982: Sept., 657-678

Cancer registry(ies), 1982: Sept., 633

Capital investment, in laboratory technology assessment, 1981: March, 41

Carbamazepine, perinatal effect of, 1981: June, 369  
 therapeutic monitoring of, 1981: Sept., 484-486

Carbohydrate metabolism, neonatal disorders of, 1981: June, 419-432

Carbon monoxide, levels, in fire victims, 1983: June, 298-299

Carbon monoxide poisoning, 1983: June, 400

Carboxyhemoglobin, levels, in fire victims, 1983: June, 299

Carboxypeptidase N, subcellular sites of, 1983: Dec., 581-584

Carcinoembryonic antigen, clearance, in primates, 1982: Sept., 459-467  
 in breast cancer, 1982: Sept., 550-555  
 in monitoring cancer, 1982: Sept., 663-664, 671-677

Carcinogen(s), safety standards for, 1983: Sept., 472

Cardiac glycosides. See *Digoxin* and *Digitoxin*.

Cardiac metabolism, computer simulation of, 1982: Dec., 711

Cardiopulmonary bypass system, 1982: March, 65-69

Cardiovascular surgery, chemotherapy in, 1982: March, 65-85

Carotene, laboratory measurement of, drug interference, 1981: Dec., 648-649

Cartridge(s), firearm. See also *Bullet(s)*.  
 primers for, 1983: June, 258-259  
 rifle, characteristics of, 1983: June, 263-264

Case-finding, definition of, 1981: March, 24

Cathepsin G, in extracellular matrix degradation, 1983: Dec., 647-648

Cathode ray tube (CRT) terminals, 1983: March, 173-174

Cavitation, in firearm wounds, 1983: June, 260, 277-281, 286-289

Cell, culture, in viral isolation, 1982: June, 384-386  
 destruction, antibody-mediated, 1982: March, 211-219  
 endothelial, in inflammatory response, 1983: Dec., 577-598

Centrifugal force, relative, in recovery of mycobacteria, 1982: June, 312

Cephalosporin(s), toxic effects, 1981: Sept., 589

Cervix, cancer, mass screening for, 1982: Sept., 628  
 screening for, 1982: Sept., 650

Chediak-Higashi syndrome, neutrophil dysfunction and, 1983: Dec., 790-791

Chemical explosions, 1983: June, 311-313

Chemical methods, in antigen detection, 1981: March, 63-64

Chemical testing, collection of specimens for, 1983: Sept., 524-529

Chemiluminescence assay, in assessment of nitrogen status, 1981: Dec., 773  
 methods of, 1981: March, 98-101

Chemotactic defect(s), in neutrophil stimulation, 1983: Dec., 787-789

Chemotactic factor(s), in neutrophil stimulation, 1983: Dec., 782-783  
 neutrophil, in burn injury, 1983: Dec., 804-806  
 in lung injury, 1983: Dec., 603-607

platelets and, 1983: Dec., 667-669

Chest, radiograph, in lung infection, 1982: June, 289-290

Chickenpox, perinatal, 1981: June, 389-390

Child(ren), battered, 1983: June, 321-342  
 profile of, 1983: June, 326-327

Child abuse, 1983: June, 321-342  
 radiographic evidence of, 1983: June, 322, 332-333  
 sudden infant death and, 1983: June, 338-342

Child abusers, profile of, 1983: June, 324-326

*Chlamydia* infection, perinatal, 1981: June, 388-389  
respiratory, laboratory diagnosis of, 1982: June, 371-382

Chloramphenicol, perinatal effect of, 1981: June, 369

toxic effects, 1981: Sept., 590-591

Chlorpromazine, therapeutic monitoring of, 1981: Sept., 551-553

Cholesterol desmolase deficiency, neonatal, 1981: June, 411

Chorionic gonadotropin, human, in germ cell tumors, 1982: Sept., 440-443

Chromatography, column, in measurement of bilirubin, 1981: June, 336-337, 339-341

Chromatography, gas-liquid, in anaerobic respiratory infection, 1982: June, 297 in mycobacterial infection, 1982: June, 317  
in prenatal diagnosis of respiratory distress syndrome, 1981: June, 204

in measurement of eicosanoids, 1983: Dec., 700

in therapeutic drug monitoring, 1981: Sept., 444-445, 460-463. See also under specific methods.

in toxicologic analysis, 1983: June, 373-374, 390-392

thin-layer, in mycobacterial infection, 1982: June, 316-317  
in prenatal diagnosis of respiratory distress syndrome, 1981: June, 205-211

Chromosome, HLA antigens and, 1982: March, 133  
linkage, blood group loci and, 1982: March, 137-141

*Citrobacter diversus* infection, neonatal, 1981: June, 351-352

Classification, of borderline disease, 1982: Dec., 744-745  
of disease, by cluster analysis, 1982: Dec., 742-744  
by pattern recognition, 1982: Dec., 720-730

Clerical tasks, computerized, in laboratory, 1983: March, 88-92, 98-100

Clindamycin, toxic effects, 1981: Sept., 590

Clinical laboratory. See also *Laboratory*.  
accreditation of, 1983: Sept., 448  
compressed gases in, 1983: Sept., 470  
electrical safety in, 1983: Sept., 470  
federal regulation of, 1983: Sept., 441-450  
fire prevention and control in, 1983:  
Sept., 468-470  
new tests in, planning and instituting, 1983: Sept., 413-422  
personnel management in, 1983: Sept., 451-463  
quality control for, 1983: Sept., 541-551

Clinical laboratory (*Continued*)  
state licensing of, 1983: Sept., 448  
state regulation of, 1983: Sept., 447  
toxic and biological hazards in, 1983:  
Sept., 472

Clothing, fibers, as evidence, 1983: June, 364-365  
postmortem examination of, 1983: June, 356-357

Clotting. See also *Coagulation*.  
defects, after cardiopulmonary bypass, 1982: March, 75-78  
of heparinized blood, 1982: March, 77

Clotting factors, changes in level, in cardiovascular surgery, 1982: March, 73-75

Clumping. See *Agglutination*.

Cluster analysis, in classification of disease, 1982: Dec., 742-744  
in pattern recognition, 1982: Dec., 724-728

Coagglutination, in antigen detection, 1981: March, 55-56

Coagulation, abnormal, in malignant disease, 1982: Sept., 604-609  
normal, 1982: Sept., 600-603

Coagulation factor(s), 1982: Sept., 602  
in cancer patients, 1982: Sept., 605-609

Coagulation tests, collection and handling of specimens for, 1983: Sept., 531

Coagulopathy, neonatal, replacement therapy in, 1981: June, 297-300

Coding of data, in laboratory information system, 1983: March, 172-173

Colchicine, for gout, 1983: Dec., 704

Cold agglutinin syndrome, 1982: March, 207-208

Colistin, toxic effects, 1981: Sept., 593

Collagen metabolite(s), in malignant disease, 1982: Sept., 519-542

Collagenase, in extracellular matrix degradation, 1983: Dec., 647-650

College of American Pathologists Laboratory Accreditation Program, 1983: Sept., 448

Colloid(s), as fluid therapy, in critically ill, 1982: March, 35-63

Colon, cancer, screening tests for, consequences of diagnostic error, 1982: Dec., 782-784

Colorectal cancer, screening tests for, consequences of diagnostic error, 1982: Dec., 782-784

Colorimetric methods, in measurement of vitamin A, 1981: Dec., 704-705

Colton system, 1982: March, 144

Combination testing, predictive value model in, 1982: Dec., 695-698  
selection of, 1982: Dec., 871-890  
by multivariate analysis, 1982: Dec., 735-750

Compatibility testing, pretransfusion, 1982: March, 169-179, 181-192  
 in autoimmune hemolytic anemia, 1982: March, 193-210  
 in cardiovascular surgery, 1982: March, 78-81

Complement, deficiency, in neutrophil dysfunction, 1983: Dec., 789  
 detection, by immunofluorescence, 1983: Dec., 757-758  
 in chemotactic defects, 1983: Dec., 788-789

Complement activation, 1982: March, 216-217; 1983: Dec., 588-590  
 alternative pathway, in burn injury, 1983: Dec., 809-810  
 classic and alternative pathways of, 1983: Dec., 578-579  
 in burn injury, 1983: Dec., 810-812  
 platelets and, 1983: Dec., 670-671

Complement component(s), effect on neutrophil chemotaxis, in burn injury, 1983: Dec., 805-806  
 effect on phagocytosis, 1982: March, 217-218  
 in burn injury, 1983: Dec., 806-807  
 in malnutrition, 1981: Dec., 639-640  
 in inflammatory response, 1983: Dec., 578-583  
 in lung injury, 1983: Dec., 603-607

Complement system, biological activities of, 1983: Dec., 808-810  
 effect of burn injury on, 1983: Dec., 808-810

Complete blood count (CBC), collection and handling of specimens for, 1983: Sept., 530

Compliance, in therapeutic drug monitoring, 1981: Sept., 469

Compressed gases, safe use of, 1983: Sept., 470

Computer information systems, applications in combination testing, 1982: Dec., 737, 741-742  
 in pattern recognition, 1982: Dec., 717-734  
 in test selection, 1982: Dec., 703, 712  
 hospital and laboratory linkage, 1983: March, 219-231  
 hospital-based, in monitoring health care, 1983: March, 179-204  
 implementation, in the laboratory, 1983: March, 233-250  
 in anatomic pathology, 1983: March, 133-147  
 in blood banking, 1983: March, 111-132  
 in clinical laboratory (symposium), 1983: March, 3-250  
 assessment of, 1981: March, 111-125  
 contracting, 1983: March, 19-34

Computer information systems (*Continued*)  
 in clinical laboratory (symposium), controlled access to, 1983: March, 174-176  
 cost analysis of, 1983: March, 63-78  
 life cycle of, 1983: March, 6-7  
 pre-acquisition analysis, 1983: March, 3-18  
 reliability of, 1983: March, 165-177  
 request for proposal, 1983: March, 19-25  
 user-designed, 1983: March, 35-50  
 vendor selection, 1983: March, 19-34  
 in clinical microbiology, 1983: March, 101-110  
 in laboratory management, 1983: March, 149-163  
 in quality control studies, 1983: Sept., 548  
 microcomputer technology and, 1983: March, 51-62  
 networking of, 1983: March, 200  
 strengths and weaknesses, 1983: March, 4-5, 80-82

Computer simulation, in models predicting cancer recurrence, 1982: Sept., 675-677  
 of cardiac metabolism, 1982: Dec., 711

Computerized axial tomography (CAT), assessment of, 1981: March, 7

Conflagration. See *Fire(s)*.

Congestive heart failure, drug therapy for, 1981: Sept., 523-533

Conjunctivitis, neonatal, 1981: June, 353

Connective tissue disease, autoimmune, 1983: Dec., 754-757

"Consequences comparison" curve, for diagnostic test, defined, 1982: Dec., 780-781

Consultants, in system development, 1983: March, 8-9

Contact wounds, from firearms, 1983: June, 267-269

Contamination, of sputum specimens, 1982: June, 260-262  
 of respiratory specimens, in anaerobic infection, 1982: June, 291-292

Contract(s), for laboratory information system, 1983: March, 19-34, 246

Coombs' test. See *Antiglobulin test*.

Copper deficiency, 1981: Dec., 757  
 laboratory assessment of, 1981: Dec., 756-759

Cori-Forbes disease, neonatal, 1981: June, 427-428

Coronary heart disease, test selection in, 1982: Dec., 792-793

Corpse, buried, identification of, 1983: June, 296-298

Corticosteroid(s), pulmonary effects, following endotoxemia, 1983: Dec., 728-729

Correlation, of multiple laboratory tests, 1982: Dec., 884-887

Cortisol, management, in pregnancy, 1981: June, 163-165

Cost analysis, in assessing computer systems, 1981: March, 118-120

in assessing diagnostic errors, 1982: Dec., 779-787

in assessing instrumentation, 1983: Sept., 437

in assessing laboratory information system, 1983: March, 63-78

in assessing laboratory technology, 1981: March, 39-47

in assessing medical technology, 1981: March, 4-5, 13-14, 35

of laboratory, 1983: Sept., 425

of laboratory tests, 1983: Sept., 413

of laboratory utilization, 1983: March, 189-193

in test evaluation, 1982: Dec., 821-833

Cost-benefit model, in therapeutic decision-making. See *Threshold approach*.

Counterimmunoelctrophoresis, in antigen detection, 1981: March, 53-55

"Crash" recovery, in laboratory information system, 1983: March, 248

Creatine kinase, in human tissue, 1982: Sept., 495

variants, in cancer, 1982: Sept., 500-502

Creatine kinase isoenzyme, in malignant disease, 1982: Sept., 489, 493-506

Crib death. See *Sudden infant death*.

Crossmatch, antiglobulin, evaluation of, 1981: March, 74

cost effectiveness of, 1982: March, 191

in emergency cardiovascular surgery, 1982: March, 78-81

preoperative, 1982: March, 169-179

pretransfusion, evaluation of, 1982: March, 181-192

pretransplantation, 1983: Dec., 765-767

Cryoprecipitate, in neonatal transfusion, 1981: June, 300-301

transfusion, 1982: March, 14-17

Crystalline compound(s), in inflammatory response, prostaglandins and, 1983: Dec., 703-704

Crystalloid(s), as fluid therapy, in critically ill, 1982: March, 35-63

Culture, anaerobic, collection and handling of specimens for, 1983: Sept., 534

bacterial, of sputum specimen, 1982: June, 262

blood, preanalytic factors in, 1983: Sept., 532

fungal, of respiratory specimens, 1982: June, 266

in recovery of *Chlamydia*, 1982: June, 377

Culture (Continued)

media, in *Legionella* infection, 1982: June, 362-363

of *Pneumocystis carinii*, 1982: June, 404

of respiratory specimens, in fungal infection, 1982: June, 325-328

stool, preanalytic factors in, 1983: Sept., 534

tissue, in viral isolation, 1982: June, 384-386

urine, preanalytic factors in, 1983: Sept., 532

Current, electrical. See *Electrical current*.

Cyanide, red cell, therapeutic monitoring of, 1982: Sept., 536

Cyanocobalamin. See *Vitamin B<sub>12</sub>*.

Cyclic AMP, concentrations, following endotoxemia, 1983: Dec., 732

in neutrophil stimulation, 1983: Dec., 785-786

Cyclic GMP, concentrations, following endotoxemia, 1983: Dec., 732

in neutrophil stimulation, 1983: Dec., 785-786

Cyclic nucleotides. See *Cyclic AMP: Cyclic GMP*.

Cyclooxygenase, inhibition of, 1983: Dec., 725-726

Cyclooxygenase pathway, of arachidonate metabolism, 1983: Dec., 679-681

Cyclosporine, in organ transplantation, 1983: Dec., 770

Cyapheresis. See specific procedure, as *Leukapheresis*.

Cytolysis, antibody-mediated, 1982: March, 211-219

Cytomegalovirus, perinatal, 1982: June, 386-388

DANISH Breast Cancer Group (DBCG) study, of tumor markers, 1982: Sept., 659-677

Data, analysis. See specific technique, as *Cluster analysis*.

bases, in automated blood bank, 1983: March, 115-117

in clinical laboratory, 1983: March, 222-223

in hospital information system, 1983: March, 179-204

in laboratory information system, 1983: March, 240

management system, 1983: March, 42

of laboratory test results, 1982: Dec., 815-816

display, in pattern recognition, 1982: Dec., 723-724

Data (*Continued*)  
 elements, in laboratory information system, 1983: March, 220-229  
 entry, in automated blood bank, 1983: March, 118-122  
 in microbiologic computer system, 1983: March, 103, 108  
 reliability, 1983: March, 173  
 management, in automated blood bank, 1983: March, 114-126  
 instrumentation needs and, 1983: Sept., 430-431  
 processing, automated. See *Computer information systems*.  
 storage, in laboratory, 1981: March, 111-125

Death, alcoholic, investigation of, 1983: June, 392-395  
 autopsy in. See *Autopsy*.  
 drug-related, investigation of, 1983: June, 368-370, 377-379  
 from electrocution, 1983: June, 343-353  
 from explosion, 1983: June, 309-319  
 from fire, 1983: June, 295-307  
 from firearm wounds, 1983: June, 257-271, 273-294  
 of battered child, investigation of, 1983: June, 327-341  
 Debranched deficiency, neonatal, 1981: June, 427-428  
 Debugging, of laboratory information system, 1983: March, 241-242  
 Decision analysis, clinical, 1981: March, 22-26  
 in selection of computer system, 1981: March, 117-123  
 in test evaluation, 1982: Dec., 764-775, 821-833  
 Decision-making, clinical, process of, 1982: Dec., 701-702  
 role of new laboratory test in, 1982: Dec., 751-777  
 in test selection, symposium on, 1982: Dec., 685-901  
 of expert clinicians, 1982: Dec., 814-815  
 Dentition. See *Teeth*.  
 Deoxyuridine suppression test, folate status and, 1981: Dec., 790-792  
 in nutritional assessment, 1981: Dec., 653  
 Depression, drug therapy for, 1981: Sept., 541-544  
 Dermatologic. See *Skin*.  
 Design defect cases, 1983: June, 402-404  
 Desipramine, therapeutic monitoring of, 1981: Sept., 541-544  
 Detonating explosions, 1983: June, 313  
 Diabetes insipidus, neonatal, 1981: June, 414-416  
 Diabetes mellitus, antibody markers of, 1983: Dec., 752

Diabetes mellitus (*Continued*)  
 in pregnancy, 1981: June, 169, 175  
 neonatal hypocalcemia and, 1981: June, 231, 421  
 neonatal respiratory distress and, 1981: June, 199, 206  
 neonatal, 1981: June, 424  
 test selection in, 1982: Dec., 796-797  
 Diagnosis, computer-assisted, in anatomic pathology, 1983: March, 143  
 Diagnosis retrieval systems, computerized, 1983: March, 134-139  
 Diagnostic tests. See *Laboratory test(ing)*.  
 Diarrhea, neonatal, 1981: June, 352-353  
 Diazepam, perinatal effect of, 1981: June, 369  
 Diego system, 1982: March, 144  
 Diet, history, in nutritional assessment, 1981: Dec., 606  
 Digitoxin, therapeutic monitoring of, 1981: Sept., 531-533  
 Digoxin, perinatal effect of, 1981: June, 369  
 therapeutic monitoring of, 1981: Sept., 525-530  
 toxic effects, 1981: Sept., 531  
 Diphenhydramine, pulmonary effects, following endotoxemia, 1983: Dec., 730-731  
 Discounting, of cash flows, 1981: March, 45-46; 1983: March, 75  
 Discriminant function analysis, in test selection, 1982: Dec., 729-730, 735-750  
 of markers, in monitoring cancer, 1982: Sept., 667-671  
 Disease, borderline, classification of, 1982: Dec., 744-745  
 classification of, by cluster analysis, 1982: Dec., 742-744  
 by pattern recognition, 1982: Dec., 720-730  
 monitoring of, serial testing in, 1982: Dec., 842-847  
 timing of laboratory tests in, 1982: Dec., 851-870  
 prevalence, predictive value and, 1982: Dec., 685  
 Disopyramide, therapeutic monitoring of, 1982: Sept., 509-511  
 toxic effects, 1981: Sept., 510-511  
 Display techniques, for data, in pattern recognition, 1982: Dec., 723-724  
 Disseminated intravascular coagulation, incompatible transfusion and, 1982: March, 228-229  
 neonatal, exchange transfusion in, 1981: June, 273  
 "Down time," of hardware, in laboratory information system, 1983: March, 167

Doxepin, therapeutic monitoring of, 1981:  
Sept., 541-544

Drug(s). See also under specific drugs.  
antiarrhythmic, investigational, 1981:  
Sept., 516-519  
therapeutic monitoring of, 1981: Sept.,  
501-522

antidepressant, therapeutic monitoring of,  
1981: Sept., 541-545

antiepileptic, therapeutic monitoring of,  
1981: Sept., 479-500

antimicrobial, therapeutic monitoring of,  
1981: Sept., 585-597

antipsychotic, therapeutic monitoring of,  
1981: Sept., 547-557

as vitamin antagonists, 1981: Dec., 652-  
654

cardiac glycosides, therapeutic monitoring  
of, 1981: Sept., 523-539

interference, in laboratory tests of  
nutritional status, 1981: Dec., 647-664

perinatal exposure, 1981: June, 361-375

pharmacokinetics, 1981: Sept., 469-474

poisoning by, investigation of, 1983: June,  
367-384

resistance, in tuberculosis, 1982: June,  
313

therapy, in anaerobic respiratory  
infection, 1982: June, 300-301

in anaphylaxis, 1983: Dec., 627

Drug(s), therapy, in inflammatory disease,  
1983: Dec., 685-689

in tuberculosis, 1982: June, 315-316

monitoring of, 1981: Sept., 439-597

toxic concentrations of, 1983: June, 381-  
382

vasoactive, therapeutic monitoring of,  
1981: Sept., 534-537

Duffy system, 1982: March, 144

Dye(s), in measurement of bilirubin, 1981:  
June, 333-336

ECONOMIC analysis, in laboratory technology  
assessment, 1981: March, 39-47

Edema, pulmonary, fluid therapy in, 1982:  
March, 39-49

following endotoxemia, 1983: Dec., 723

Education, in use of laboratory technology,  
1981: March, 13-17

Efficiency, of laboratory test, 1981: March,  
31-32

Eicosanoid(s). See specific substance, as  
*Prostaglandin(s); Thromboxane(s)*.

Elastase, in extracellular matrix degradation,  
1983: Dec., 647-651

in inflammatory response, 1983: Dec.,  
583-585

in neutrophil-mediated lung injury, 1983:  
Dec., 611

Electrical burns. See *Burn(s), electrical*.

Electrical current, 1983: June, 347-352

Electrical equipment, faulty, examination of,  
1983: June, 349-352

Electrical explosions, 1983: June, 310-311

Electrical injury, 1983: June, 310-311, 343-  
353

    blood in, 1983: June, 346

    from lightning, 1983: June, 352-353

Electrical safety, 1983: Sept., 470

Electricity, atmospheric. See *Lightning*.  
    physics of, 1983: June, 343-344

    types of, 1983: June, 347-353

Electrocution, 1983: June, 343-353

    by defective product, 1983: June, 349-  
    352, 403

Electroimmunodiffusion, in measurement of  
alpha-fetoprotein, 1981: June, 188-189

Electrolyte analysis, collection of specimens  
for, 1983: Sept., 524

Electrophoresis, acrylamide gel slab, in  
measurement of alpha-fetoprotein,  
1981: June, 189-192

    of glycoproteins, 1982: Sept., 472-474

Embolism, pulmonary, test selection in,  
1982: Dec., 792

Encryption, of date, in laboratory  
information system, 1983: March, 172-  
173

Endocrine disease, autoimmune, 1983:  
Dec., 750-753

Endocrine function, laboratory evaluation of,  
1982: Dec., 796-797, 803-819

Endocrine studies, collection and handling  
of specimens for, 1983: Sept., 528

    in monitoring pregnancy, 1981: June,  
    157-179

Endocrine system, neonatal disorders of,  
1981: June, 399-418

Endothelial cell(s). See *Endothelium*.

Endothelium, complement inactivation and,  
1983: Dec., 579-581

    in inflammatory response, 1983: Dec.,  
    577-598

injury to, following endotoxemia, 1983:  
Dec., 723

    granulocytes and, 1983: Dec., 737-739

neutrophil adherence to, in lung injury,  
1983: Dec., 603-605

permeability of, by neutrophils, 1983:  
Dec., 607-612

response to injury, 1983: Dec., 586-592

Endotoxemia, lung injury and, 1983: Dec.,  
719-744

Endotoxin, affect on neutrophils, in lung  
injury, 1983: Dec., 605

    immunosuppressive effects, in burn  
    injury, 1983: Dec., 803

Entrance wounds, firearm, 1983: June, 264-  
270

Environment, physical, for hardware, 1983: March, 169, 238-240

Enzyme(s). See also specific enzymes, as *Carboxypeptidase; Angiotensin converting enzyme*. activity, in cancer, 1982: Sept., 479-491 analysis, 1983: Sept., 526-528 assay, in measurement of bilirubin, 1981: June, 337 in measurement of riboflavin, 1981: Dec., 691-693 in breast cancer, 1982: Sept., 547 in malignant disease, 1982: Sept., 493-506 pancreatic, in cancer, 1982: Sept., 482-483 Enzyme deficiency(ies), neonatal, 1981: June, 407-412 Enzyme immunoassays, 1981: March, 80-88 future potential of, 1981: March, 96-97 heterogeneous, 1981: March, 81-86 in therapeutic drug monitoring, 1981: Sept., 456-457 homogeneous, 1981: March, 86-88 in therapeutic drug monitoring, 1981: Sept., 456 thermistor analysis in, 1981: March, 99 Enzyme markers, of myocardial infarction, 1982: Dec., 707-708 Enzyme Multiplied Immunoassay Technique (EMIT), in monitoring antiepileptics, 1981: Sept., 490-491 in monitoring theophylline, 1981: Sept., 566-567 in therapeutic drug monitoring, 1981: Sept., 456 Enzyme testing, predictive value model in, 1982: Dec., 687, 696-698 Enzyme-channeling immunoassay, homogeneous, 1981: March, 96 Enzyme-linked immunosorbent assay (ELISA), in microbial antigen detection, 1981: March, 58-60 of pancreas-specific antigen, 1982: Sept., 572-574 Epilepsy, drug therapy for, 1981: Sept., 479-500 Ergonomic design, of laboratory information system, 1983: March, 173-174 Error, diagnostic, in laboratory testing, 1982: Dec., 779-787 Erythrapheresis, therapeutic, 1982: March, 101-102 Erythroblastosis fetalis. See *Hemolytic disease*. Erythrocyte(s), agglutination, 1982: March, 155-167 destruction, antibody-radiated, 1982: March, 211-219 frozen, transfusion of, 1981: March, 70 Erythrocyte(s) (Continued) in neonatal transfusion, 1981: June, 285-292 leukocyte-poor, transfusion of, 1981: March, 69-70 transfusion of, 1981: March, 68-71; 1982: March, 8-10 in critically ill, 1982: March, 52 washed, 1982: March, 224, 245-246 transfusion of, 1981: March, 70 Erythrocyte antigens, 1982: March, 144-146 Rh system and, in hemolytic disease of newborn, 1982: March, 107-122 typing, in autoimmune hemolytic anemia, 1982: March, 198-199 Erythrocyte bilirubin uptake, in measurement of bilirubin, 1981: June, 332-333 Erythrocyte enzyme tests, of vitamin status, drug interference, 1981: Dec., 651-652 Erythrocyte membrane, 1982: March, 155-159 agglutination and, 1982: March, 161-162 Erythroid disorder(s), test selection in, 1982: Dec., 708 Erythromycin, toxic effects, 1981: Sept., 590 *Escherichia coli* infection, neonatal, 1981: June, 350-353 Essential fatty acids, laboratory assessment of, 1981: Dec., 618, 665-672 Estrogen(s), measurement of, in pregnancy, 1981: June, 165-169 Ethambutol, toxic effects, 1981: Sept., 595 Ethanol. See *Alcohol*. Ethosuximide, therapeutic monitoring of, 1981: Sept., 489-490 Ethyl alcohol. See *Alcohol, ethyl*. Evidence, blood samples of, 1983: June, 360-362 in explosions and bombings, 1983: June, 305, 317-318 in fires, 1983: June, 303-304 in product liability deaths, 1983: June, 403 radiographic, in child abuse, 1983: June, 322, 332-333 in firearm wounds, 1983: June, 269-270 toxicologic, 1983: June, 375-383, 392-395 trace, 1983: June, 355-365 Exchange transfusion, in neonate, 1981: June, 265-283 Expert witness, in product liability case, 1983: June, 401-402 Explosion(s). See also *Bombing(s)*. chemical, 1983: June, 311-313 electrical, 1983: June, 310-311 gas, 1983: June, 312-313 injuries from, 1983: June, 304-305, 309-319 mechanical, 1983: June, 309-310

Explosion(s) (*Continued*)  
  physics of, 1983: June, 309-313  
Explosive(s), classification of, 1983: June, 311-313

FACTOR(S), coagulation. See *Coagulation factors(s)* or under specific factor, as *Fibrinogen*.

Factor VIII, in cancer patients, 1982: Sept., 606-607

Factor replacement, in neonatal transfusion, 1981: June, 297-300

Failure to thrive, evaluation of, 1983: June, 337-338

False negatives, consequences of, in laboratory diagnosis, 1982: Dec., 779-787

False positives, consequences of, in laboratory diagnosis, 1982: Dec., 779-787

False-positive rate, defined, 1982: Dec., 689-690

Fatty acids, essential, deficiency, 1981: Dec., 666  
  laboratory assessment of, 1981: Dec., 618, 665-672

Fc receptors, 1983: Dec., 579-581

Feasibility study, for laboratory information system, 1983: March, 63-78

Federal government, in regulation of clinical laboratory, 1983: Sept., 441-447

Ferritin, in breast cancer, 1982: Sept., 547  
  levels, iron status and, 1981: Dec., 736

Fetal-maternal hemorrhage, dose of Rh immune globulin and, 1982: March, 115-117

Fetoplacental unit, endocrinology of, 1981: June, 158-160

Fetus, bacterial infection in, 1981: June, 345-360  
  blood sampling, 1981: June, 215-225  
  drug exposure in, 1981: June, 361-375  
  heart rate monitoring in, blood sampling and, 1981: June, 219-222  
  lung maturity, prenatal evaluation of, 1981: June, 199-213  
  neural tube defects, prenatal diagnosis of, 1981: June, 181-198  
  nonbacterial infection in, 1981: June, 377-397  
  syphilis in, 1981: June, 355-359

Fever, total parenteral nutrition and, 1981: Dec., 627

Fibers, as evidence, 1983: June, 364-365

Fibrillation, ventricular, in electrical injury, 1983: June, 347, 349, 352

Fibrinogen, in cancer patients, 1982: Sept., 605-606

Fibrinolysis, abnormal, in malignant disease, 1982: Sept., 609-616  
  normal, 1982: Sept., 603-604

Fibronectin, effect on phagocytosis, in burn injury, 1983: Dec., 806-807

Fingernail(s), as evidence, 1983: June, 358, 363

Fingerprinting, of unidentified corpse, 1983: June, 297

Fire(s), death from, investigation of, 1983: June, 295-307  
  prevention and control, in laboratory, 1983: Sept., 468-470

Firearm(s). See also *Rifled weapon(s)*.  
Firearm wounds, 1983: June, 257-271, 273-294  
  bullet track in, 1983: June, 260, 277-281, 286-289  
  contact, 1983: June, 267-269  
  distant range, 1983: June, 264-266  
  intermediate range, 1983: June, 266-267  
  of head, 1983: June, 265-268, 287-288  
  of liver, 1983: June, 285-287  
  of muscle, 1983: June, 283-285

Flora, indigenous, in anaerobic pleuropulmonary infection, 1982: June, 286-287

Flow-analysis technology, in leukocyte differential counting, 1981: March, 127-150

Fluid(s), body, alcohol levels in, 1983: June, 386-395  
  drug levels in, 1983: June, 369-370

Fluid therapy, algorithms, in critically ill, 1982: March, 53-60  
  in critically ill, 1982: March, 35-63

Fluorescence, assay, in measurement of bilirubin, 1981: June, 337  
  in measurement of riboflavin, 1981: Dec., 691  
  in measurement of vitamin A, 1981: Dec., 705-709  
  in measurement of vitamin C, 1981: Dec., 680

Fluorescent antibody technique, in antigen detection, 1981: March, 50-53

Fluorescent antinuclear antibody test, in SLE, 1982: Dec., 881-884

Fluorescent treponemal antibody absorption test (FTA-Abs), in syphilis, 1981: June, 358-359

Fluoroimmunoassay(s), 1981: March, 88-91  
  future potential of, 1981: March, 97  
  heterogeneous, 1981: March, 88-90  
  in therapeutic drug monitoring, 1981: Sept., 458-459

homogeneous, 1981: March, 90-95  
  in therapeutic drug monitoring, 1981: Sept., 458

Fluorometer, types of, 1981: March, 90

Fluphenazine, therapeutic monitoring of, 1981: Sept., 554-555

Folacin. See *Folate*.

Folate, antagonists, 1981: Dec., 653  
deficiency, 1981: Dec., 782-784  
laboratory assessment of, 1981: Dec., 775-796  
drug interference, 1981: Dec., 650-651

Folic acid. See *Folate*.

Forensic pathology, symposium on, 1983: June, 257-405

Forensic toxicology, 1983: June, 385-396

Formatting of information, in computerized laboratory, 1983: March, 79-100. See also *Report format(s)*.

FORTRAN, 1983: March, 6-7. See also *Programming languages*.

Fracture(s), in battered child, 1983: June, 322-323, 332-333  
in fire victims, 1983: June, 302  
in firearm wounds, 1983: June, 282-283

Fructose metabolism, neonatal disorders of, 1981: June, 424-426

Fungus(i), opportunistic pulmonary infection, laboratory diagnosis of, 1982: June, 407-413  
respiratory infection, laboratory diagnosis of, 1982: June, 321-342

Furosemide, perinatal effect of, 1981: June, 370

GALACTOSEMIA, neonatal, 1981: June, 429-430

Galactosyltransferase, as tumor marker, 1982: Sept., 475

Galactosyltransferase isoenzyme II, in pancreatic cancer, 1982: Dec., 876-878

Gamma-glutamyltranspeptidase, in hepatic cancer, 1982: Sept., 483-484

Gas(es), blood, collection and handling of specimens for, 1983: Sept., 525  
compressed, safe use of, 1983: Sept., 470  
explosive limits of, 1983: June, 312

Gas chromatography, in microbial antigen detection, 1981: March, 63-64

Gas explosions, 1983: June, 312-313

Gas-liquid chromatography, in anaerobic respiratory infection, 1982: June, 297  
in monitoring acetaminophen, 1981: Sept., 578  
in monitoring antiepileptics, 1981: Sept., 490-491  
in monitoring ethanol, 1981: Sept., 582-583  
in monitoring theophylline, 1981: Sept., 566-567  
in mycobacterial infection, 1982: June, 317

Gas-liquid chromatography (Continued)  
in prenatal diagnosis of respiratory distress syndrome, 1981: June, 204  
in therapeutic drug monitoring, 1981: Sept., 461-462

Gastrointestinal tract, cancer, CK<sub>1</sub> activity in, 1982: Sept., 497

Gelatinase, in extracellular tissue degradation, 1983: Dec., 647-648

Gene mapping, of blood group loci, 1982: March, 137-141

Genetic factors, in autoimmune disorders, 1983: Dec., 746  
in chronic granulomatous disease, 1983: Dec., 792

Gentamicin, perinatal effect of, 1981: June, 370

Germ cell tumor(s), extragonadal, markers for, 1982: Sept., 454-456  
infantile, 1982: Sept., 447  
markers for, 1982: Sept., 431-458

German measles. See *Rubella*.

Giemsa stain, in *Pneumocystis* infection, 1982: June, 399

Glass, as evidence, 1983: June, 363-364

Glucocorticosteroid(s), affect on inflammatory response, 1983: Dec., 708

Glucose. See *Carbohydrate* or under disorders such as *Hypoglycemia*.

Glucose determinations, 1983: Sept., 525

Glucose-6-phosphatase deficiency, neonatal, 1981: June, 426-427

Glycogen storage diseases, neonatal, 1981: June, 426-428

Glycoprotein(s), as tumor markers, 1982: Sept., 469-477

Glycoside, cardiac. See *Digoxin* and *Digitoxin*.

Glycosyltransferase(s), in breast cancer, 1982: Sept., 547  
in cancer, 1982: Sept., 485-487

Gonad(s), germ cell tumors of, markers for, 1982: Sept., 431-458

Gonadotropin, human chorionic, in germ cell tumors, 1982: Sept., 440-443  
measurement of, in pregnancy, 1981: June, 170-172

Graphic output, in laboratory information system, 1983: March, 155

Graft, rejection, mechanisms of, 1983: Dec., 764-765

Graft-versus-host disease, blood transfusion and, 1982: March, 130  
in marrow transplantation, 1982: March, 129

Gram's stain, in anaerobic respiratory infection, 1982: June, 296-297  
in evaluation of respiratory specimens, 1982: June, 265  
in *Legionella* infection, 1982: June, 356-357

Gram-Weigert stain, in *Pneumocystis* infection, 1982: June, 401-403

Granulocyte(s), in endotoxin-induced lung injury, 1983: Dec., 732-739

transfusion of, 1981: March, 72-73

in neonate, 1981: June, 295-296

Granulomatous disease, chronic, neutrophil dysfunction and, 1983: Dec., 792

Graves' disease, 1983: Dec., 750

neonatal, 1981: June, 258, 406-407

Gross cystic disease fluid protein (GCFDP-15), in breast cancer, 1982: Sept., 555-558

Group B streptococcus infection, neonatal, 1981: June, 348-350

Growth hormone deficiency, neonatal, 1981: June, 412-414

Gun. See *Firearm(s)*.

Gunshot wounds. See *Firearm wounds*.

HAIR, analysis of, 1983: June, 370

in fire deaths, 1983: June, 298

as evidence, 1983: June, 357, 363

Hardware, microcomputer, 1983: March, 53

reliability, in laboratory information system, 1983: March, 166-169

security, in laboratory information system, 1983: March, 169-170

selection, in user-designed system, 1983: March, 45-46

Hardware configuration, in laboratory information system, 1983: March, 238

Hardware installation, in laboratory information system, 1983: March, 238-240

Hardware maintenance, in laboratory information system, 1983: March, 235

contract for, 1983: March, 32-33

Hashimoto's disease, 1983: Dec., 750

Hazardous wastes, disposal of, 1983: Sept., 477-480

Head wounds, from firearms, 1983: June, 265-268, 287-288

in battered child, 1983: June, 328-336

Health care, computerized evaluation of, 1983: March, 179-204

Health Insurance Plan (HIP) study, for breast cancer, 1982: Sept., 627-638

Heart. See also *Cardiac*.

attack. See *Myocardial infarction*.

disease, coronary, test selection in, 1982: Dec., 792-793

failure, congestive, drug therapy for, 1981: Sept., 523-533

transplantation, 1983: Dec., 773-774

ventricular fibrillation, in electrical injury, 1983: June, 347, 349, 352

Hemapheresis, therapeutic, 1982: March, 87-106. See also specific type of therapy, as *Leukapheresis*.

Hematofluorometer, bilirubin, 1981: June, 338

Hematologic malignancy(ies), CK<sub>1</sub> activity in, 1982: Sept., 499-500

Hematologic testing, preanalytic factors in, 1983: Sept., 529-531

Hematology, technology assessment in, 1981: March, 127-150

Hematology laboratory, safety standards for, 1983: Sept., 477

Hematoma, in fire victims, 1983: June, 301-303

subdural, in battered child, 1983: June, 334

Hemochromatosis, HLA-A antigen and, 1982: March, 132

idiopathic, iron status and, 1981: Dec., 732-735

Hemocytoblast. See *Stem cell*.

Hemoglobinuria, paroxysmal cold, 1982: March, 208-209

Hemolysis, antibodies and, 1982: March, 211-219

Hemolytic disease, multiple laboratory testing in, 1982: Dec., 696-698

Hemolytic disease of newborn, 1981: June, 246-254; 1982: March, 107-122

exchange transfusion in, 1981: June, 265-269

Hemolytic transfusion reactions, 1982: March, 79, 221-231

Hemorrhage in battered child, 1983: June, 334-335

in fire victims, 1983: June, 301-303

maternal-fetal, dose of Rh immune globulin and, 1982: March, 115-117

Hemostasis, abnormal, in malignant disease, 1982: Sept., 599-625

Hemosiderin. See *Iron*.

Hemotherapy, symposium on, 1982: March, 3-252. See also specific procedures, as *Leukapheresis*.

Hepatic. See also *Liver*.

Hepatic necrosis, acetaminophen-induced, 1981: Sept., 575-576

Hepatitis, type A, perinatal, 1981: June, 391-392

type B, perinatal, 1981: June, 392-393

viral, transfusion-transmitted, 1982: March, 233-252

Hepatitis A virus, 1982: March, 240-241

Hepatitis B immune globulin (HBIG), 1982: March, 247

Hepatitis B surface antigen, detection of, 1981: March, 53, 57-58, 60

Hepatitis B virus, 1982: March, 241-242

Hepatitis non-A, non-B, 1982: March, 242-243  
 Herpes simplex virus infection, perinatal, 1981: June, 384-386  
 Hersh disease, neonatal, 1981: June, 428  
 HETE. See *Hydroxyeicosatetraenoic acid*.  
 High performance liquid chromatography (HPLC), in measurement of vitamin A, 1981: Dec., 709  
 in measurement of vitamin D, 1981: Dec., 723-724  
 in monitoring acetaminophen, 1981: Sept., 578  
 in monitoring antiepileptics, 1981: Sept., 490-491  
 in monitoring salicylate, 1981: Sept., 573  
 in monitoring theophylline, 1981: Sept., 566-567  
 in therapeutic drug monitoring, 1981: Sept., 462  
 Histamine, hyperresponsiveness to, following endotoxemia, 1983: Dec., 720-722  
 in anaphylaxis, 1983: Dec., 619-620  
 in endotoxin-induced lung injury, 1983: Dec., 729-730  
 Histologic methods, in assessment of iron status, 1981: Dec., 737  
 Histocompatibility complex. See *HLA*.  
 Histocompatibility testing, mixed lymphocyte culture and, 1982: March, 128  
 Hit-and-run accident, collection of evidence in, 1983: June, 357, 364  
 HLA antigens, disease associations and, 1982: March, 130-132; 1983: Dec., 747-748  
 HLA loci, 1982: March, 123-125  
 HLA typing, clinical applications of, 1982: March, 123-135  
 pretransplantation, 1983: Dec., 776  
 Hodgkin's disease, classification of, 1982: Sept., 589  
 Homeostatic autoregressive model, in monitoring cancer, 1982: Sept., 672-677  
 Homicide, attempted concealment of, 1983: June, 299  
 Hormonal assays, in monitoring pregnancy, 1981: June, 157-179  
 Hormonal disorders, of neonate, 1981: June, 399-418  
 Hormone(s). See also specific types.  
 urinary, 1983: Sept., 529  
 Hospital, accreditation of, Joint Commission on, 1983: Sept., 447  
 Hospital information system, linkage with laboratory information system, 1983: March, 219-231  
 medical applications, 1983: March, 179-204  
 Host defense(s), effect on burn injury on, 1983: Dec., 801-802  
 HPETE. See *Hydroperoxyeicosatetraenoic acid*.  
 Human chorionic gonadotropin, measurement of, in pregnancy, 1981: June, 170-172  
 Hybridoma method, in production of monoclonal antibodies, 1981: March, 99-105  
 Hybridoma technology, in organ transplantation, 1983: Dec., 777  
 Hydroperoxyeicosatetraenoic acid, chemotactic activity of, 1983: Dec., 669  
 in anaphylaxis, 1983: Dec., 621-625  
 in neutrophil stimulation, 1983: Dec., 786-787  
 production of, 1983: Dec., 681  
 Hydroxybenzeneazobenzoic acid, in albumin dye-binding, 1981: June, 334-335  
 Hydroxyeicosatetraenoic acid, chemotactic activity of, 1983: Dec., 669  
 in anaphylaxis, 1983: Dec., 621-625  
 in endotoxin-induced lung injury, 1983: Dec., 728  
 in neutrophil stimulation, 1983: Dec., 786-787  
 macrophage-derived, in inflammatory response, 1983: Dec., 684-688  
 production of, 1983: Dec., 680-682  
 11-Hydroxylase deficiency, neonatal, 1981: June, 410-411  
 17-Hydroxylase deficiency, neonatal, 1981: June, 411-412  
 21-Hydroxylase deficiency, neonatal, 1981: June, 408-410  
 Hydroxyproline, in malignant disease, 1982: Sept., 519-542  
 Hyperalimentation. See *Parenteral nutrition*.  
 Hyperbilirubinemia, neonatal, causes of, 1981: June, 314-315  
 exchange transfusion in, 1981: June, 269-272  
 management of, 1981: June, 341-342  
 Hypercalcemia, drug-induced, 1981: Dec., 658  
 laboratory evaluation of, 1982: Dec., 809-812  
 vitamin D status and, 1981: Dec., 722-723  
 Hyperglycemia, neonatal, 1981: June, 424  
 Hyperinsulinism. See *Hypoglycemia*.  
 Hyperkalemia, drug-induced, 1981: Dec., 657  
 Hyperleukocytosis, leukapheresis and, 1982: March, 98-99  
 Hypermagnesemia, drug-induced, 1981: Dec., 659  
 Hypernatremia, drug-induced, 1981: Dec., 655

Hyperparathyroidism, test selection in, 1982: Dec., 809-812

Hyperphosphatemia, drug-induced, 1981: Dec., 659  
neonatal, 1981: June, 233-234

Hyperplasia, congenital adrenal, 1981: June, 407-412

Hypersensitivity reaction(s). See *Anaphylaxis*.

Hypertension, consequences of diagnostic error, 1982: Dec., 784-785  
test selection in, 1982: Dec., 793-796

Hyperthyroidism, neonatal, 1981: June, 258, 400, 406-407  
test selection in, 1982: Dec., 797-798

Hyperviscosity syndrome, plasmapheresis and, 1982: March, 95-96

Hypocalcemia, drug-induced, 1981: Dec., 657-658  
neonatal, 1981: June, 227-238

Hypoglycemia, neonatal, 1981: June, 420-423

Hypokalemia, drug-induced, 1981: Dec., 655-657

Hypomagnesemia, drug-induced, 1981: Dec., 658-659  
neonatal, 1981: June, 234-235

Hyponatremia, drug-induced, 1981: Dec., 654-655

Hypophosphatemia, drug-induced, 1981: Dec., 659

Hypotensive agent(s), therapeutic monitoring of, 1981: Sept., 534-537

Hypothermia, therapeutic, in cardiovascular surgery, 1982: March, 82-84

Hypothyroidism, neonatal, 1981: June, 400-406  
test selection in, 1982: Dec., 797-798

**ICTERUS.** See *Jaundice* or *Kernicterus*.

**Icterus neonatorum.** See *Hemolytic disease of newborn*.

IgA, secretory, in malnutrition, 1981: Dec., 640-641

Imidazole, affect on inflammatory response, 1983: Dec., 707

Imipramine, therapeutic monitoring of, 1981: Sept., 541-544

Immune adherence, in cell destruction, 1982: March, 212-215

Immune disorder(s), laboratory diagnosis of, 1983: Dec., 745-761

Immune globulin, prophylaxis, for hepatitis, 1982: March, 246-248

Immune response. See also *Inflammatory response*.  
in graft rejection, 1983: Dec., 764-765  
prostaglandins and, 1983: Dec., 700-701  
tissue, symposium on, 1983: Dec., 577-817

Immune serum globulin, in neonatal transfusion, 1981: June, 301-303

Immunity, cell-mediated, in burn injury, 1983: Dec., 801-802

Immunization, active, for hepatitis, 1982: March, 248  
passive, for hepatitis, 1982: March, 246-248

Immunoassay(s), enzyme, 1981: March, 80-88  
in viral respiratory infection, 1982: June, 389

in therapeutic drug monitoring, 1981: Sept., 444-445, 453-460. See also under specific methods.

in toxicologic analysis, 1983: June, 374-375

light scattering, 1981: March, 78-79  
technology of, 1981: March, 77-109

Immunocompetence, assessment of, in malnutrition, 1981: Dec., 631-645

Immunoelectrophoresis, radiotissue, for alpha-fetoprotein, 1982: Sept., 443-444

Immunoenzymatic methods, in cancer, 1982: Sept., 581-582

Immunofluorescence techniques, direct, in *Legionella* infection, 1982: June, 357-361  
in microbial antigen detection, 1981: March, 50-53

in cancer, 1982: Sept., 580-581

in chlamydial respiratory infection, 1982: June, 377-378

in detection of autoantibodies, 1983: Dec., 757-758

in viral respiratory infection, 1982: June, 387-389

indirect, in *Legionella* infection, 1982: June, 350-356  
versus fluoroimmunoassay, 1981: March, 88-89

Immunogenicity, pretransplantation alteration of, 1983: Dec., 767-768

Immunoglobulin(s). See also *Antibody(ies)*.  
detection, by immunofluorescence, 1983: Dec., 757-758

effect on phagocytosis, in burn injury, 1983: Dec., 806-807

function of, 1981: June, 239-244

in antibody-mediated perinatal disease, 1981: June, 244-246

in cytolysis, 1982: March, 212-215

replacement, in neonate, 1981: June, 301-303

Immunologic methods, in microbial antigen detection, 1981: March, 50-63  
in *Pneumocystis* infection, 1982: June, 403

preanalytic factors in, 1983: Sept., 535

Immunology, clinical, technology assessment in, 1981: March, 77-109

malnutrition and, 1981: Dec., 631-645

organ transplantation and, 1983: Dec., 763-778

Immunomodulation, pretransplantation, 1983: Dec., 770

Immunopathology, tissue, symposium on, 1983: Dec., 577-817

Immunoperoxidase technique(s), direct, in microbial antigen detection, 1981: March, 52  
in detection of autoantibodies, 1983: Dec., 758-759  
indirect, for human chorionic gonadotropin, 1982: Sept., 443

Immunosuppressive factors, in burn injury, 1983: Dec., 802-804

Immunosuppressive therapy, complications of, 1983: Dec., 772-773  
pretransplantation, 1983: Dec., 768-770

Incident reports, 1983: Sept., 476

Indomethacin, in inflammatory response, 1983: Dec., 688, 707  
perinatal effect of, 1981: June, 370

Infant(s), sudden death, 1983: June, 338-342

Infarction, myocardial. See *Myocardial infarction*.

Infection, bacterial, in neonate, 1981: June, 345-360  
chlamydial, laboratory diagnosis of, 1982: June, 371-382  
fungal, in respiratory tract, laboratory diagnosis of, 1982: June, 321-342  
hepatitis, transfusion-transmitted, 1982: March, 233-252  
*Legionella*, laboratory diagnosis of, 1982: June, 343-369  
mycobacterial, laboratory diagnosis of, 1982: June, 305-319  
nonbacterial, in neonate, 1981: June, 377-397  
nosocomial respiratory, laboratory diagnosis of, 1982: June, 415-423  
opportunistic fungal, laboratory diagnosis of, 1982: June, 407-413  
pneumopulmonary, laboratory diagnosis of, 1982: June, 285-303  
*Pneumocystis*, laboratory diagnosis of, 1982: June, 393-406  
respiratory, invasive diagnostic techniques in, 1982: June, 269-283  
laboratory diagnosis of, 1982: June, 259-423  
viral respiratory, laboratory diagnosis of, 1982: June, 383-391

Infection control, role of laboratory in, 1982: June, 415-423

Infectious disease, immunologic diagnostic techniques, 1981: March, 49-65

Inflammatory cell(s). See also specific cell type, as *Neutrophil(s)*; *Macrophage(s)*; *Monocyte(s)*.  
neutral proteinases of, 1983: Dec., 645-666

Inflammatory disease(s), drug therapy for, 1981: Sept., 567-573

Inflammatory disease(s) (*Continued*)  
macrophage arachidonic acid metabolites in, 1983: Dec., 685-689  
neutral proteinases in, 1983: Dec., 645-666

Inflammatory response, endothelium and, 1983: Dec., 577-598  
in burn injury, 1983: Dec., 801-815  
in lung, 1983: Dec., 601-617  
macrophage arachidonic acid metabolites in, 1983: Dec., 684-685  
mediators of, 1983: Dec., 577-592, 619-643  
neutrophils and, 1983: Dec., 779-800  
platelets and, 1983: Dec., 667-676  
prostaglandins and, 1983: Dec., 695-717

Information format(s). See *Report format(s)*.

Information processing, analysis, in clinical laboratory, 1983: March, 11-12, 38, 79-100, 236  
in clinical laboratory vs. anatomic pathology, 1983: March, 134

Information requirements, in clinical laboratory, 1983: March, 220-229. See also *Data elements*; *Data bases*.

Information systems, computerized. See *Computer information systems*.

laboratory, assessment of, 1981: March, 111-125

Instrumentation, evaluation of, 1983: Sept., 423-439  
financial justification and cost analysis of, 1983: Sept., 437  
for stat testing, 1983: Sept., 501  
operational characteristics of, 1983: Sept., 429  
quality control for, 1983: Sept., 549  
requirements for, analysis of, 1983: Sept., 427-431

Insulin, sensitivity, estimation of, 1982: Dec., 708

Interfacial tension, cell-cell interactions and, 1982: March, 162-163

Interferon, endotoxin-induced, in burn injury, 1983: Dec., 803

Interpretive reporting, in clinical laboratory, 1983: March, 205-217

Interval, occult, of laboratory test, 1982: Dec., 852-854

Iron, deficiency, 1981: Dec., 733-734  
laboratory assessment of, 1981: Dec., 729-741  
levels, effect of drugs on, 1981: Dec., 660

Iron deficiency anemia, laboratory evaluation of, 1982: Dec., 751-777

Isoniazid, toxic effects, 1981: Sept., 595-596

JAUNDICE, hemolytic disease of newborn and, 1981: June, 267-268; 1982: March, 115

**Jaundice (Continued)**  
neonatal, management of, 1981: June, 341-342

**Job descriptions, for clinical laboratory, 1983:** Sept., 456

**Job grades, for clinical laboratory, 1983:** Sept., 457

**Joint Commission on Accreditation of Hospitals, 1983:** Sept., 447

**KELL system, 1982:** March, 143-144

**Kernicterus, neonatal, bilirubin levels and, 1981:** June, 329-343  
exchange transfusion in, 1981: June, 271-272

**Kidney, failure, after transfusion, 1982:** March, 225  
transplantation, 1983: Dec., 771-772  
HLA typing in, 1982: March, 125-129

**Kinin(s), in anaphylaxis, 1983:** Dec., 620  
in endotoxin-induced lung injury, 1983: Dec., 730-731

**Kwashiorkor, 1981:** Dec., 768-771

**LABOR, fetal blood sampling and, 1981:** June, 215-225

**Laboratory.** See also *Clinical laboratory; Laboratory medicine.*  
analysis, in planning for automated system, 1983: March, 3-18  
anatomic pathology, 1983: Sept., 477  
clinical communications in, 1982: Dec., 803-819  
computer information systems in (symposium), 1983: March, 3-251.  
See also *Computer information systems.*  
role in diagnosis of respiratory infection, 1982: June, 259-263  
role in technology assessment (chart), 1981: March, 16  
utilization of, 1982: Dec., 891-901  
computer-based information systems in, assessment of, 1981: March, 111-125  
cost analysis of, 1983: Sept., 425  
design of, specifications for, 1983: Sept., 492  
equipment, in therapeutic drug monitoring, 1981: Sept., 442-444  
extent of mycobacterial services, 1982: June, 310  
functional status of, analysis of, 1983: Sept., 423-427  
planning and design for, 1983: Sept., 486  
goals of, 1983: Sept., 426  
hematology, 1983: Sept., 477

**Laboratory (Continued)**  
management, automated, 1983: March, 149-163  
measurement systems in, 1983: Sept., 553-570  
microcomputer-based automation of, 1983: March, 56-57  
symposium on, 1983: Sept., 411-570  
methods, assessing clinical utility of, 1981: March, 21-37  
microbiology, immunologic diagnostic methods in, 1981: March, 49-65  
nuclear medicine, safety regulations for, 1983: Sept., 474-476  
planning and design of, 1983: Sept., 483-496  
problems in, 1983: Sept., 493  
quality control for, 1983: Sept., 541-551  
reference selection of, 1983: Sept., 507-521  
role in nosocomial infection, 1982: June, 415-423  
service, organization of, 1981: Sept., 439-450  
technology. See also *Technology* and under specific procedures.  
cost analysis, 1981: March, 4-5, 13-14, 35, 39-47, 118-120  
in therapeutic drug monitoring, 1981: Sept., 451-466  
toxicology, 1983: June, 367-384, 385-396  
utilization patterns, automated management of, 1983: March, 156-157  
cost analysis of, 1983: March, 189-193  
work-in-process workload, reduction of, 1983: March, 92-98  
workload analysis of, 1983: Sept., 424

**Laboratory information systems.** See also *Computer information systems, in clinical laboratory.*  
linkage with hospital information system, 1983: March, 219-231  
request for proposal, 1983: March, 19-25  
user-designed, 1983: March, 31, 35-50

**Laboratory measurements.** See also *Laboratory tests.*  
in cancer, assessment of, 1982: Sept., 657-678  
in evaluation of hemostasis, 1982: Sept., 616-617  
in malignant disease, symposium on, 1982: Sept., 431-478  
of collagen metabolites, 1982: Sept., 519-522  
of eicosanoids, 1983: Dec., 699-700  
of glycoproteins, 1982: Sept., 472-474  
of polyamines, 1982: Sept., 508-510  
**Laboratory medicine, technology assessment in, 1981:** March, 3-19  
symposium on, 1981: March, 1-150

Laboratory safety, regulation of, 1983: Sept., 445, 480  
 requirements for, 1983: Sept., 465-482  
 selected publications for, 1983: Sept., 481

Laboratory test(ing), accuracy of, determining, 1983: Sept., 417  
 Laboratory test(ing), assessing clinical utility of, 1981: March, 21-37  
 benefit-risk analysis in, 1981: March, 25-26  
 clinical, evaluation of, 1982: Dec., 821-833  
 computerized functions in, 1983: March, 102-103  
 costs of, 1983: Sept., 413  
 diagnostic errors and, 1982: Dec., 779-787  
 drug interference in, 1981: Dec., 647-664  
 effectiveness, predictive value and, 1982: Dec., 685-699  
 experimental investigation of, 1983: Sept., 416-419  
 in assessment of copper status, 1981: Dec., 757-759  
 in assessment of fatty acids, 1981: Dec., 665-672  
 in assessment of folate status, 1981: Dec., 775-796  
 in assessment of iron status, 1981: Dec., 735-740  
 in assessment of nutritional status, 1981: Dec., 605-796  
 in assessment of parenteral nutrition, 1981: Dec., 611-630  
 in assessment of protein status, 1981: Dec., 767-774  
 in assessment of riboflavin status, 1981: Dec., 690-693  
 in assessment of vitamin A status, 1981: Dec., 704-710  
 in assessment of vitamin C status, 1981: Dec., 677-682  
 in assessment of vitamin D status, 1981: Dec., 716-719  
 in assessment of zinc status, 1981: Dec., 747-756  
 in autoimmune disorders, 1983: Dec., 745-761  
 in clinical decision-making, 1981: March, 11, 22-24  
 in combination, predictive value model in, 1982: Dec., 695-698  
 in evaluation of endocrine function, 1982: Dec., 803-819  
 in monitoring disease, timing of, 1982: Dec., 851-870  
 in series, functions of, 1982: Dec., 835-850  
 in therapeutic drug monitoring, 1981: Sept., 451-466  
 interpretive reporting and, 1983: March, 210-214

Laboratory test(ing) (*Continued*)  
 marketing, 1983: Sept., 420  
 monitoring as rationale for, 1981: March, 10  
 multiple, correlation of, 1982: Dec., 884-887  
 interpretation of, 1982: Dec., 814-815  
 selection of, 1982: Dec., 871-890  
 new, planning and instituting, 1982: Dec., 751-777; 1983: Sept., 413-422  
 objectives, 1983: March, 206-208  
 physicians' patterns of use, 1981: March, 9-12  
 precision of, determining, 1983: Sept., 416  
 preliminary investigation of, 1983: Sept., 412  
 reference range of, 1983: Sept., 419  
 report formats, 1983: March, 79-100. See also *Report format(s)*.  
 selection, biodynamic models and, 1982: Dec., 701-715  
 by multivariate analysis, 1982: Dec., 735-750  
 in clinical problems, 1982: Dec., 789-802. See also under specific problem, as *Myocardial infarction*.  
 pattern recognition in, 1982: Dec., 717-734  
 strategies for, symposium on, 1982: Dec., 685-901  
 "threshold approach" to, 1981: March, 11, 26, 32-35; 1982: Dec., 871-872  
 usage, surveillance of, 1982: Dec., 891-901

Labor laws, federal, 1983: Sept., 446  
 Lactate dehydrogenase, in cancer, 1982: Sept., 487-488  
 Lactoferrin, deficiency, in neutrophil dysfunction, 1983: Dec., 791-792  
 Lactogen, placental, measurement of, 1981: June, 172-173  
 Latex agglutination test, in antigen detection, 1981: March, 55-56  
 Lavage, bronchoalveolar, in respiratory infection, 1982: June, 276-277  
 Leadership, development of, 1983: Sept., 452  
 Lecithin, fetal lung maturation and, 1981: June, 202  
 Lecithin/sphingomyelin ratio, in assessment of fetal lung maturity, 1981: June, 205-211  
*Legionella*, classification of, 1982: June, 345  
 isolation of, 1982: June, 345-350  
*Legionella* infection(s), laboratory diagnosis of, 1982: June, 343-369  
*Legionella pneumophila*, detection of, 1981: March, 51  
 Legionnaire's disease, laboratory diagnosis of, 1981: March, 51; 1982: June, 343-369

Leukapheresis, therapeutic, 1982: March, 97-100

Leukemia, acute lymphoblastic, classification of, 1982: Sept., 582-583

acute myeloblastic, classification of, 1982: Sept., 584

chronic, leukapheresis and, 1982: March, 99-100

chronic lymphocytic, classification of, 1982: Sept., 584-585

CK, activity in, 1982: Sept., 499-500

classification, immunologic techniques in, 1982: Sept., 579-597

lysozyme activity in, 1982: Sept., 484

TdT activity in, 1982: Sept., 484-485

Leukocyte(s). See also Neutrophil(s); *Granulocyte(s)*; *Lymphocyte(s)*.

differential count, automation by flow-analysis, 1981: March, 127-150

in neonatal transfusion, 1981: June, 295-296

Leukocyte-poor red blood cells, transfusion of, 1981: March, 69-70

Leukocyte terminal deoxynucleotidyl transferase (TdT) activity, in malnutrition, 1981: Dec., 641-643

Leukotriene(s), in anaphylaxis, 1983: Dec., 621-625

in endotoxin-induced lung injury, 1983: Dec., 728

in neutrophil-mediated lung injury, 1983: Dec., 610-611

in neutrophil stimulation, 1983: Dec., 786-787

production of, 1983: Dec., 681-684

Lidocaine, perinatal effect of, 1981: June, 370-371

therapeutic monitoring of, 1981: Sept., 511-513

toxic effects, 1981: Sept., 512-513

Lightning, injury from, 1983: June, 311, 352-353

Light scattering assays, 1981: March, 78-79

in therapeutic drug monitoring, 1981: Sept., 459-460

"Likelihood quotients," in test evaluation, 1982: Dec., 759-764

Lipemia, effects on bilirubin measurement, 1981: June, 317-318

Lipid(s). See also specific substances, as *Prostaglandin(s)*; *Platelet-activating factor*.

analysis of, 1983: Sept., 525

metabolism, in neutrophil stimulation, 1983: Dec., 786-787

Lipoxygenase pathway, inhibition, 1983: Dec., 728-729

of arachidonate metabolism, 1983: Dec., 680-681

*Listeria monocytogenes* infection, neonatal, 1981: June, 354-355

Lithium, therapeutic monitoring of, 1981: Sept., 544-545

toxic effects, 1981: Sept., 544-545

Litigation, product liability, 1983: June, 397

role of pathologist in, 1983: June, 397-405

"Little-ticket" technology, assessment of, 1981: March, 7-8

Liver, autoimmune diseases of, 1983: Dec., 749-750

cancer,  $\gamma$ GTP activity in, 1982: Sept., 483-484

LDH activity in, 1982: Sept., 487-488

disease, in primates, CEA clearance and, 1982: Sept., 459-467

test selection in, 1982: Dec., 708-709, 735-750, 799

inflammation, transfusion-transmitted, 1982: March, 233-252

injury, from firearms, 1983: June, 285-287

necrosis, acetaminophen-induced, 1981: Sept., 575-576

transplantation, 1983: Dec., 772-773

Lung, abscess, radiographic appearance, 1982: June, 289-290

anaerobic infection, diagnosis of, 1982: June, 285-303

aspiration, in respiratory infection, 1982: June, 278-279

biopsy, in *Pneumocystis* infection, 1982: June, 395-396

in respiratory infection, 1982: June, 275-276

cancer, CK<sub>1</sub> activity in, 1982: Sept., 496-497

hydroxyproline in, 1982: Sept., 532-534

screening for, 1982: Sept., 646

heart and, transplantation, 1983: Dec., 774

injury, following skin burns, 1983: Dec., 810-812

mechanisms of, 1983: Dec., 601-617

septicemia and, 1983: Dec., 719-744

open biopsy, in respiratory infection, 1982: June, 279-280

Lupus erythematosus, systemic, antibody markers of, 1983: Dec., 754-757

prostaglandins and, 1983: Dec., 705-706

test selection in, 1982: Dec., 880-884

Lutheran system, 1982: March, 143

Lymph node(s), metastatic, as predictor of recurrent breast cancer, 1982: Sept., 661-664

Lymphocyte(s), depletion of.

pretransplantation, 1983: Dec., 769-770

effect of burn injury on, 1983: Dec., 801-802

in pretransplantation crossmatch, 1983: Dec., 765-766

**Lymphocyte(s) (Continued)**

- thymus-dependent, in autoimmune disorders, 1983: Dec., 638-639
- in malnutrition, 1981: Dec., 638-639

**Lymphoma, malignant, classification of, immunologic techniques in, 579-597**

**Lymphopenia, in malnutrition, 1981: Dec., 633**

**Lysozyme, in leukemia, 1982: Sept., 484**

**MCARDLE'S disease, neonatal, 1981: June, 428**

**Macrocytosis, folate status and, 1981: Dec., 788-789**

**Macrophage(s), activation, arachidonic acid metabolism and, 1983: Dec., 677-694**

**neutral proteinases of, 1983: Dec., 650-652**

**role in proteolysis, 1983: Dec., 657-658**

**suppressive effects of prostaglandins on, 1983: Dec., 685**

**Magnesium, levels, effect of drugs on, 1981: Dec., 658-659**

- in neonate, 1981: June, 234-235

**Maintenance, of laboratory information system, 1983: March, 235. See also Hardware; Software.**

**Malignant disease. See also Cancer.**

- laboratory measurements in, symposium on, 1982: Sept., 431-678**

**Malnutrition. See under specific disorders, such as Kwashiorkor.**

**Management, automated functions, in clinical laboratory, 1983: March, 149-163**

**of laboratory, symposium on, 1983: Sept., 411-570**

**of medical laboratories, measurement systems in, 1983: Sept., 553-570**

**Mania, drug therapy for, 1981: Sept., 544-545**

**Manual versus automated information systems, in blood banking, 1983: March, 126-130**

**cost analysis, 1983: March, 67-76**

**Marasmus, 1981: Dec., 768**

**Marrow, transplantation, HLA typing in, 1982: March, 128-129**

**Massachusetts General Hospital microbiology system, 1983: March, 106-107**

**Mass screening, criteria for, 1982: Sept., 629-630**

- for cancer, 1982: Sept., 627-638

**Mass spectrometry-gas chromatography, in antigen detection, 1981: March, 63-64**

**Mathematical model(s), biodynamic, in test selection, 1982: Dec., 701-715**

- for timing of repeated tests, 1982: Dec., 851-870

**Mathematical model(s) (Continued)**

- in cancer screening, 1982: Sept., 634-635
- in monitoring cancer, 1982: Sept., 657-678

**Mean corpuscular volume, in iron deficiency anemia, 1982: Dec., 758-764**

**Mean time between failures (MTBF), in laboratory information system, 1983: March, 167**

**Mean time to repair (MTTR), in laboratory information system, 1983: March, 167**

**Measurement systems, in management of medical laboratories, 1983: Sept., 553-570**

**Mechanical explosions, 1983: June, 309-310**

**Meclofenamate sodium, pulmonary effects, following endotoxemia, 1983: Dec., 725-727**

**Media, culture, in isolation of anaerobes, 1982: June, 297-298**

- in isolation of fungi, 1982: June, 326-328
- in isolation of Legionella, 1982: June, 345-350

**Mediator(s), of endotoxin-induced lung injury, 1983: Dec., 719-744**

**of inflammatory response. See specific substance, as Histamine.**

**Medicaid, 1983: Sept., 442**

**Medical care, computerized evaluation of, 1983: March, 179-204**

**Medical decision-making, computer-supported, 1983: March, 183-189**

**Medical diagnosis, laboratory testing in. See under Laboratory testing.**

**Medical technology. See Laboratory technology.**

**Medicare, 1983: Sept., 441**

**Medulla. See Marrow.**

**Megaloblastosis, folate status and, 1981: Dec., 789-790**

**Membrane, of red blood cell, 1982: March, 155-159**

**Menkes' kinky hair syndrome, copper status and, 1981: Dec., 757**

**Meperidine, perinatal effect of, 1981: June, 371**

**Message(s), computer-generated, 1983: March, 183-186. See also Report format(s).**

**Metabolite(s), of arachidonic acid. See specific substances, as Prostaglandin(s); Leukotriene(s).**

**Metastases, to bone, prediction of, in breast cancer, 1982: Sept., 525-527**

- in lung cancer, 1982: Sept., 532-534
- in multiple myeloma, 1982: Sept., 536
- in prostatic cancer, 1982: Sept., 531

**Methotrexate, as vitamin antagonist, 1981: Dec., 653**

Metronidazole, toxic effects, 1981: Sept., 594

MGH Utility Multi-Programming System (MUMPS), 1983: March, 6-7, 106-107

Microagglutination (MA) test, in *Legionella* infection, 1982: June, 354

Microbial antigen(s), detection by immunologic technique, 1981: March, 49-65

Microbiologic assay(s), of riboflavin status, 1981: Dec., 691

Microbiologic hazards, 1983: Sept., 473

Microbiologic testing, preanalytic factors in, 1983: Sept., 531-535

Microbiology, clinical, microbial antigen detection and, 1981: March, 49-65

computer information systems in, 1983: March, 101-110

microcomputer-based systems in, 1983: March, 56

Microbiology laboratory, safety requirements of, 1983: Sept., 473

Microbiology specimen brush, 1982: June, 293-294

Microcomputers, in clinical laboratory, 1981: March, 115; 1983: March, 51-62

Microimmunofluorescence (MIF), in chlamydial respiratory infection, 1982: June, 377-378

Microprocessor(s), 1983: March, 53

in user-designed system, 1983: March, 39-40

Microscopy, in evaluation of sputum, 1982: June, 260-262

in fungal respiratory infection, 1982: June, 328-329

Milk, breast, drugs excreted in, 1981: June, 367

Milk protein(s), in breast cancer, 1982: Sept., 545

Mineral(s), laboratory assessment of, 1981: Dec., 618-619. See also under specific minerals.

Minicomputer(s), in user-designed system, 1983: March, 40

Missile wounds. See *Firearm wounds*.

MNSs system, 1982: March, 141-142

Model(s), biodynamic, in test selection, 1982: Dec., 701-715

mathematical, for timing of repeated tests, 1982: Dec., 851-870

in cancer screening, 1982: Sept., 634-635

in monitoring cancer, 1982: Sept., 657-678

Monitoring, of test use, 1982: Dec., 891-901

patient, serial testing in, 1982: Dec., 842-847

timing of laboratory tests in, 1982: Dec., 851-870

Monitoring (*Continued*)

patient, use of laboratory tests for, 1981: March, 9-10

Monoclonal antibodies, as reagents, 1981: March, 99-105

in autoimmune disorders, 1983: Dec., 759-760

in organ transplantation, 1983: Dec., 777

Monocyte(s), neutral proteinases of, 1983: Dec., 649-650

role in proteolysis, 1983: Dec., 657-658

Multiple testing, evaluation of efficiency, 1982: Dec., 760-764

predictive value model in, 1982: Dec., 695-698

selection of, 1982: Dec., 871-890

Multiple univariate analysis, in test selection, 1982: Dec., 737-738

Multiple variate analysis, in test selection, 1982: Dec., 735-750

MUMPS, 1983: March, 6-7, 106-107

Muramidase, in leukemia, 1982: Sept., 484

Muscle, alcohol levels in, 1983: June, 387

injury, from firearms, 1983: June, 283-285

Muscular disease, autoimmune, 1983: Dec., 753

Myasthenia gravis, antibody markers of, 1983: Dec., 753

neonatal, 1981: June, 257-258

Mycobacteria, nomenclature, 1982: June, 308-309

Mycobacterial infection, laboratory diagnosis of, 1982: June, 305-319

Mycosis(es), of respiratory tract, laboratory diagnosis of, 1982: June, 321-342, 407-413

Myeloma, multiple, hydroxyproline in, 1982: Sept., 534-536

Myocardial infarction, size, prediction of, 1982: Dec., 710

test selection in, 1982: Dec., 707-708, 791-792

N-ACETYLCYSTEINE (NAC), as antidote, 1981: Sept., 577

N-acetylpromocainamide (NAPA), therapeutic monitoring of, 1981: Sept., 507-509

Nafazatrom, in inflammatory response, 1983: Dec., 688

Nails, of fingers. See *Fingernail(s)*.

Nalidixic acid, toxic effects, 1981: Sept., 594

National Institute of Health (NIH) microbiology system, 1983: March, 107

*Neisseria gonorrhoeae* infection, neonatal, 1981: June, 353-354

Neonate, alloimmune neutropenia in, 1981: June, 255-256

**Neonate (Continued)**

- alloimmune thrombocytopenia in, 1981: June, 254-255
- antibody-mediated disease in, 1981: June, 239-263
- autoimmune hemolytic anemia in, 1981: June, 258-259
- autoimmune thrombocytopenic purpura in, 1981: June, 257
- bacterial infection in, 1981: June, 345-360
- bilirubin levels in, 1981: June, 311-327
- blood component therapy in, 1981: June, 285-309
- carbohydrate metabolism disorders in, 1981: June, 419-432
- chlamydial pneumonitis in, 1982: June, 372
- congenital adrenal hyperplasia in, 1981: June, 407-412
- diabetes insipidus in, 1981: June, 414-416
- diabetes mellitus in, 1981: June, 424
- drug exposure in, 1981: June, 361-375
- endocrine disorders in, 1981: June, 399-418
- exchange transfusion in, 1981: June, 265-283
- fructose metabolism disorders in, 1981: June, 424-426
- Graves' disease in, 1982: June, 258, 406-407
- galactosemia in, 1981: June, 429-430
- glycogen storage diseases in, 1981: June, 426-428
- growth hormone deficiency in, 1981: June, 412-414
- hemolytic disease of, 1981: June, 246-254
- exchange transfusion in, 1981: June, 265-269
- hyperglycemia in, 1981: June, 424
- hyperphosphatemia in, 1981: June, 233-234
- hyperthyroidism in, 1981: June, 258
- hypocalcemia in, 1981: June, 227-238
- hypoglycemia in 1981: June, 420-423
- hypomagnesemia in, 1981: June, 234-235
- iron status and, 1981: Dec., 731-732
- myasthenia gravis in, 1981: June, 257-258
- nonbacterial infection in, 1981: June, 377-397
- reserve albumin binding capacity in, 1981: June, 329-343
- respiratory alkalolemia in, 1981: June, 235
- systemic lupus erythematosus in, 1981: June, 258
- thyroid disorders in, 1981: June, 399-407
- Neoplastic disease. See *Cancer*.
- Nephelometric assay, 1981: March, 78-79
- Networking, of computer information systems, 1983: March, 200
- of HIS/LIS systems, 1983: March, 229-230
- Neural tube defect(s), prenatal diagnosis of, 1981: June, 181-198
- Neutropenia, alloimmune, neonatal, 1981: June, 255-256
- Neutrophil, altered function, in burn injury, 1983: Dec., 804-808
- chemotaxis, in burn injury, 1983: Dec., 804-806
- disorders of stimulus-response coupling, 1983: Dec., 779-800
- hypersegmentation, folate status and, 1981: Dec., 786-787
- impaired function, in malnutrition, 1981: Dec., 641
- interaction with platelets, in, inflammatory response, 1983: Dec., 673
- neutral proteinases of, 1983: Dec., 647-649
- role in lung injury, 1983: Dec., 601-617
- role in proteolysis, 1983: Dec., 654-657
- stimulation, mechanisms of, 1983: Dec., 780-787
- vascular permeability and, 1983: Dec., 607-612
- Newborn. See *Neonate*.
- Nicotine, perinatal effect of, 1981: June, 371
- Nitrofuranoin, toxic effects, 1981: Sept., 594
- Nitrogen, balance, laboratory assessment of, 1981: Dec., 771-773
- Nitroglycerin, therapeutic monitoring of, 1981: Sept., 536-537
- Nitroprusside, therapeutic monitoring of, 1981: Sept., 534-536
- toxic effects, 1981: Sept., 535
- Non-Hodgkin's lymphoma(s), classification of, 1982: Sept., 585-589
- Nonsteroidal anti-inflammatory drug(s) (NSAIDs), affect on prostaglandins, 1983: Dec., 706-708
- in asthmatics, 1983: Dec., 628
- Nordihydroguaiaretic acid, in inflammatory response, 1983: Dec., 688
- Nortriptyline, therapeutic monitoring of, 1981: Sept., 541-544
- Nosocomial infection(s), in neonate, 1981: June, 345-360
- respiratory, laboratory diagnosis of, 1982: June, 415-423
- Nuclear medicine, safety regulations for, 1983: Sept., 474
- 5'-Nucleotidase, in cancer, 1982: Sept., 482
- Nucleotide(s), cyclic. See *Cyclic AMP; Cyclic GMP*.
- Nutrient, deficiencies. See under specific nutrient, as *Vitamin C*, or condition, as *Scurvy*.
- solutions, for parenteral nutrition, 1981: Dec., 617-626
- Nutrition, inadequate, immunocompetence and, 1981: Dec., 631-645
- profile, 1981: Dec., 605-609

Nutrition (*Continued*)  
total parenteral, laboratory assessment of, 1981: Dec., 611-630

Nutritional index, for postoperative complications, 1981: Dec., 616-617

Nutritional status, drug interference in laboratory assessment, 1981: Dec., 647-664  
laboratory assessment of, 1981: Dec., 605-796

ODOR(S), drugs and, 1983: June, 376

Ohm's law, 1983: June, 344

Oliguria, fluid therapy in, 1982: March, 56-57

Opsonin(s), effect on phagocytosis, in burn injury, 1983: Dec., 806-807

Oral cavity, indigenous flora in, 1982: June, 286-287

Organ(s), body, alcohol levels in, 1983: June, 387  
drug levels in, 1983: June, 369-370  
injury to, in battered child, 1983: June, 336  
preservation, for transplantation, 1983: Dec., 766  
transplantation, immunologic principles and, 1983: Dec., 763-778

Osteomalacia, vitamin D status and, 1981: Dec., 720-721, 723

Ovary, germ cell tumor of, markers for, 1982: Sept., 453-454

Overdose. See also *Poisoning; Forensic toxicology*.  
of acetaminophen, 1981: Sept., 575-577  
of alcohol, 1981: Sept., 582-583  
of salicylate, 1981: Sept., 570-572

Oxidant(s), as proteinase inhibitors, 1983: Dec., 653  
generation of, by granulocytes, 1983: Dec., 737  
in inflammatory response, 1983: Dec., 583-585  
in lung injury, 1983: Dec., 812  
in neutrophil-mediated lung injury, 1983: Dec., 611-612  
in neutrophil stimulation, 1983: Dec., 781-782

Oxolinic acid, toxic effects, 1981: Sept., 594

PAF. See *Platelet-activating factor*.

Paint, as evidence, 1983: June, 364

PALI, 1983: March, 180

Pancreas, cancer, enzymatic activity in, 1982: Sept., 482-483  
immunodiagnosis of, 1982: Sept., 567-578  
test selection in, 1982: Dec., 876-878

Pancreas (*Continued*)  
transplantation, 1983: Dec., 774-776

Pancreas-specific antigen (PaA), in pancreatic cancer, 1982: Sept., 567-578

Paracetamol. See *Acetaminophen*.

Parallel testing, of laboratory information system, 1983: March, 241  
of user-designed system, 1983: March, 47

predictive value model in, 1982: Dec., 695-698  
selection of, 1982: Dec., 871-890

Parathyroid disease, test selection in, 1982: Dec., 809-812  
vitamin D status and, 1981: Dec., 722

Parenteral nutrition, total, folate deficiency and, 1981: Dec., 782  
laboratory assessment of, 1981: Dec., 611-630

Particle aggregation assays, 1981: March, 79  
in therapeutic drug monitoring, 1981: Sept., 460

Paternity testing, HLA typing in, 1982: March, 133

Pathogen(s). See specific etiologic agent.

Pathology, anatomic, computer information systems in, 1983: March, 133-147  
forensic, symposium on, 1983: June, 257-405

Patient care, computerized evaluation of, 1983: March, 179-204  
enhancement, in computerized laboratory, 1983: March, 82-88

Pattern recognition, in test interpretation, 1982: Dec., 814-815  
in test selection, 1982: Dec., 717-734

Pay scales, determination of, 1983: Sept., 458

Penicillin, in anaerobic respiratory infection, 1982: June, 300  
perinatal effect of, 1981: June, 371  
toxic effects, 1981: Sept., 588-589

Percutaneous lung aspiration (PLA), in respiratory infection, 1982: June, 278-279

Perinatal diagnosis, symposium on, 1981: June, 157-432

Perinatal disease, antibody-mediated, 1981: June, 239-263  
diagnosis of, 1981: June, 157-432

Peripheral devices, in laboratory information system, 1983: March, 46  
in user-designed system, 1983: March, 42, 45

"Personal computers," 1983: March, 3-4, 51-62

Personnel, in automated clinical laboratory, cost analysis, 1983: March, 72-74  
selection, 1983: March, 236  
training, 1983: March, 24, 47, 240, 245  
of medical laboratory, management of, 1983: Sept., 553-570  
nontesting activities, 1983: Sept., 560-561

Personnel management, 1983: Sept., 451–463  
 counseling in, 1983: Sept., 462  
 disciplinary action and, 1983: Sept., 462  
 performance evaluation in, 1983: Sept., 461  
 style of, 1983: Sept., 453  
 tools for, 1983: Sept., 454

Phage typing, in staphylococcal infection, 1981: June, 347–348

Phagocyte(s). See *Macrophage(s); Neutrophil(s); Monocyte(s)*.

Phagocytosis, antibody-mediated, 1982: March, 211–215  
 complement and, 1982: March, 216–218  
 inhibitors, in burn injury, 1983: Dec., 806–807

Pharmacokinetics, of drugs, 1981: Sept., 469–474

Pharmacology, perinatal, 1981: June, 361–375

Phenobarbital, perinatal effect of, 1981: June, 371  
 therapeutic monitoring of, 1981: Sept., 483–484

Phenolsulfonphthalein, in albumin dye-binding, 1981: June, 333–334

Phenothiazine(s), therapeutic monitoring of, 1981: Sept., 547–557  
 toxic effects, 1981: Sept., 555

Phenylethyl malondiamine (PEMA), therapeutic monitoring of, 1981: Sept., 488–489

Phenytoin, perinatal effect of, 1981: June, 371–372  
 therapeutic monitoring of, 1981: Sept., 480–483, 513–514  
 toxic effects, 1981: Sept., 514

Pheochromocytoma, test selection in, 1982: Dec., 793–795

Pheresis, technology of, 1981: March, 71–72

Phosphatase, acid type, in prostatic cancer, 1982: Sept., 480–481; 1982: Dec., 692–695  
 alkaline type, in cancer, 1982: Sept., 481–482

Phosphatidyl glycerol, in prenatal diagnosis of respiratory distress syndrome, 1981: June, 207–211

Phosphohexose isomerase, in cancer, 1982: Sept., 488–489

Phosphorus, levels, effect of drugs on, 1981: Dec., 659  
 in neonate, 1981: June, 233–234

Phototherapy, bilirubin levels and, 1981: June, 363–364

Placental lactogen, measurement of, 1981: June, 172–173

Plasma, components of, 1981: March, 73  
 derivatives, in neonatal transfusion, 1981: June, 296–303

Plasma (*Continued*)  
 exchange. See *Plasmapheresis*.  
 fresh frozen, transfusion, 1981: March, 68–69; 1982: March, 13–14

Plasmapheresis, in hemolytic disease of newborn, 1982: March, 119–120  
 physiology of, 1982: March, 89–91  
 pretransplantation, 1983: Dec., 769–770  
 therapeutic, 1982: March, 91–97

Plasminogen activator, in extracellular tissue degradation, 1983: Dec., 649–650

Platelet(s), in complement activation, 1983: Dec., 670–671  
 in endotoxin-induced lung injury, 1983: Dec., 739–740  
 in inflammatory response, 1983: Dec., 667–676  
 interaction with microorganisms, in inflammatory response, 1983: Dec., 672  
 interaction with neutrophils, in inflammatory response, 1983: Dec., 673

Platelet-activating factor, in anaphylaxis, 1983: Dec., 621–625  
 in inflammatory response, 1983: Dec., 669–670  
 production of, 1983: Dec., 626

Platelet-derived growth factor, chemotactic activity of, 1983: Dec., 668, 671–672

Platelet factor(s), 1982: Sept., 602  
 chemotactic activity of, 1983: Dec., 668

Platelet transfusion, 1981: March, 71–72; 1982: March, 10–13  
 HLA typing in, 1982: March, 129  
 in neonate, 1981: June, 292–295

Plateletpheresis, therapeutic, 1982: March, 100–101

Pleura, anaerobic infection, laboratory diagnosis of, 1982: June, 285–303

*Pneumocystis carinii* antigen, detection of, 1981: March, 54

*Pneumocystis* infection, laboratory diagnosis of, 1982: June, 393–406

Pneumonia, bronchoalveolar lavage and, 1982: June, 276–277  
 fungal, laboratory diagnosis of, 1982: June, 407–413  
*Legionella*, laboratory diagnosis of, 1982: June, 343–369  
 nosocomial, laboratory diagnosis of, 1982: June, 415–423

Pneumonitis, chlamydial, laboratory diagnosis of, 1982: June, 371–382

Poison(s), analysis of. See *Toxicologic analysis*.  
 toxic concentrations of, 1983: June, 381–382

Poisoning, drug. See under specific drugs.  
 ethyl alcohol, toxicologic analysis in, 1983: June, 385–396

Polyamine(s), in malignant disease, 1982: Sept., 507–518

Polymorphonuclear leukocyte(s). See *Neutrophil(s)*.

Polymyxin, toxic effects, 1981: Sept., 593

Pompe's disease, neonatal, 1981: June, 427

Porphyria cutanea tarda, iron status and, 1981: Dec., 732

Potassium, levels, effect of drugs on, 1981: Dec., 655-657

Powder tattooing, 1983: June, 266-267

Precision, in quality control studies, 1983: Sept., 547

Predictive value, effect of test correlation on, 1982: Dec., 884-887

in laboratory testing, 1981: March, 27-32

in test evaluation, 1982: Dec., 685-699  
753-764

of screening test, 1982: Sept., 643

Pregnancy, drugs in, 1981: June, 361-363

high risk, laboratory monitoring of, 1981: June, 157-179

Pregnanediol, measurement of, in pregnancy, 1981: June, 162-163

Present value, of cash flows, 1981: March, 45-46

Pressure, effects, in explosions, 1983: June, 314

Pretransfusion testing, type and screen in, 1982: March, 169-179

Prevalence, of disease, effect on predictive value, 1981: March, 11, 28-29

effect on test performance, 1982: Dec., 754-755

Primer, for firearm cartridges, 1983: June, 258-259

residue from, as evidence, 1983: June, 355-360

Primidone, therapeutic monitoring of, 1981: Sept., 487-489

Probability, posterior, defined, 1982: Dec., 688-689

prior, defined, 1982: Dec., 688-689

Problem solving, clinical, in laboratory, 1982: Dec., 789-802

process of, 1982: Dec., 701-702

Procainamide, therapeutic monitoring of, 1981: Sept., 507-509

toxic effects, 1981: Sept., 508-509

Product liability, 1983: June, 397-405

Profiling, definition of, 1981: March, 24

Progesterone, measurement of, in pregnancy, 1981: June, 162-163

Program(s). See *Software*.

Programmed accelerated laboratory investigation (PALI), 1983: March, 180

Programming languages, for microcomputers, 1983: March, 53

Project team, for system development, 1983: March, 7-8, 233-234

Projectile(s), firearm. See *Bullets; Cartridges*.

Prolactin, measurement of, in pregnancy, 1981: June, 173-174

Proposal. See *Request for proposal*.

Propranolol, therapeutic monitoring of, 1981: Sept., 514-516

toxic effects, 1981: Sept., 515

Prostaglandin(s), in anaphylaxis, 1983: Dec., 621-625

in endotoxin-induced lung injury, 1983: Dec., 724-725

in inflammatory response, 1983: Dec., 585-586; 695-717

in neutrophil-mediated lung injury, 1983: Dec., 605-610

in neutrophil stimulation, 1983: Dec., 786-787

macrophage-derived, in inflammatory response, 1983: Dec., 684-689

production of, 1983: Dec., 680-684

Prostate, cancer, acid phosphatase in, 1982: Sept., 480-481

hydroxyproline in, 1982: Sept., 528-532

test selection in, 1982: Dec., 692-695

Protease(s), neutral, role in neutrophil-mediated lung injury, 1983: Dec., 611

Protein(s) acute phase, secretion of, model for, 1982: Dec., 710-711

synthesis of, 1982: Sept., 472-473

associated with pregnancy, in breast cancer, 1982: Sept., 548-549

complement. See *Complement*.

cytosol, in breast cancer, 1982: Sept., 547-548

degradation of, inflammatory cell-mediated, 1983: Dec., 652-658

lactic, in breast cancer, 1982: Sept., 545

malnutrition, laboratory assessment of, 1981: Dec., 767-774

proteolytic fragments of, biologic activity of, 1983: Dec., 658-659

Proteinase(s), inhibitors of, 1983: Dec., 652-654

neutral, in extracellular matrix degradation, 1983: Dec., 645-666

Proteolytic enzyme(s), in extracellular matrix degradation, 1983: Dec., 645-666

Protoporphyrin, levels, in assessment of iron status, 1981: Dec., 739

Protriptyline, therapeutic monitoring of, 1981: Sept., 541-544

Pruritis, periumbilical, laboratory diagnosis of, 1982: Dec., 858-867

Psychosis, drug therapy for, 1981: Sept., 547-557

Pulmonary. See also *Lung*.

Pulmonary cancer, CK<sub>1</sub> activity in, 1982: Sept., 496-497

hydroxyproline in, 1982: Sept., 532-534

Pulmonary embolism, test selection in, 1982: Dec., 792

Pulmonary function, following endotoxemia, 1983: Dec., 720-723

Pulmonary infection(s). See under *Infection* or specific type or agent of infection.

Putrescine, in malignant disease, 1982: Sept., 507-518

**QUALITY control, automated system, in clinical laboratory, 1983: March, 151-153**

in automated blood bank, 1983: March, 127-128

for the clinical laboratory, 1983: Sept., 541-551

in therapeutic drug monitoring, 1981: Sept., 448

microbased programs, 1983: March, 54 of workload recording system, 1983: Sept., 562-563

Quinidine, therapeutic monitoring of, 1981: Sept., 503-507

toxic effects, 1981: Sept., 505-506

**RADIOGRAPHY, in battered child, 1983: June, 322, 332-333**

in fire deaths, 1983: June, 298, 306

in firearm wounds, 1983: June, 269-270

Radioimmunoassay, for prostatic acid phosphatase, in cancer screening, 1982: Dec., 692-695

in measurement of alpha-fetoprotein, 1981: June, 187

in microbial antigen detection, 1981: March, 56-58

in therapeutic drug monitoring, 1981: Sept., 453-455

in toxicologic analysis, 1983: June, 374-375

in viral respiratory infection, 1982: June, 389

Randomized controlled trial(s) (RCT), for cancer screening programs, 1982: Sept., 633-634

Rape-homicide, collection of evidence in, 1983: June, 358, 361-362

Reaction, Arthus, prostaglandins and, 1983: Dec., 706

Reagent(s), interchangeability of, 1981: March, 80-81

monoclonal antibodies as, 1981: March, 99-105

Receiver operating characteristic (ROC) curve, 1981: March, 31-32, 34

in test evaluation, 1982: Dec., 825-832

of screening test, 1982: Sept., 641-642

Rectum, cancer of, screening tests for, consequences of diagnostic error, 1982: Dec., 782-784

Recurrence, of breast cancer, prediction of, 1982: Sept., 657-678

Red blood cells. See *Erythrocyte(s)*.

Red cell enzyme tests, of vitamin status, drug interference, 1981: Dec., 651-652

Reference interval(s), 1982: Sept., 661-664

Reference laboratory services, requirements for, 1983: Sept., 509

selection of, 1983: Sept., 507-521

Regan isoenzyme(s), in cancer, 1981: Sept., 481

Registry(ies), of cancer incidence, 1982: Sept., 633

Regulation, congressional, of medical technology, 1981: March, 5-7

executive, of medical technology, 1981: March, 6-7, 9

Reliability, of laboratory information system, 1983: March, 165-177

Renal failure, after transfusion, 1982: March, 225

Report format(s), in anatomic pathology, 1983: March, 140-142

in computerized laboratory, 1983: March, 79-100, 237

in microbiologic computer system, 1983: March, 104-106

interpretive, in computerized laboratory, 1983: March, 205-217

Reporting, interactive, in anatomic pathology, 1983: March, 142-143

interpretive, in clinical laboratory, 1983: March, 205-217

Request for proposal (RFP), for laboratory information system, 1983: March, 9-10, 19-25

Respiratory distress syndrome, adult, fluid therapy in, 1982: March, 39-49

inflammatory response and, 1983: Dec., 601-617

septicemia and, 1983: Dec., 719-744

neonatal, exchange transfusion in, 1981: June, 273

pathogenesis of, 1981: June, 200-202

prenatal diagnosis of, 1981: June, 199-213

Rape-syndrome, collection of evidence in, 1983: June, 358, 361-362

Reaction, Arthus, prostaglandins and, 1983: Dec., 706

Reagent(s), interchangeability of, 1981: March, 80-81

monoclonal antibodies as, 1981: March, 99-105

Receiver operating characteristic (ROC) curve, 1981: March, 31-32, 34

in test evaluation, 1982: Dec., 825-832

of screening test, 1982: Sept., 641-642

Rectum, cancer of, screening tests for, consequences of diagnostic error, 1982: Dec., 782-784

Recurrence, of breast cancer, prediction of, 1982: Sept., 657-678

Red blood cells. See *Erythrocyte(s)*.

Red cell enzyme tests, of vitamin status, drug interference, 1981: Dec., 651-652

Reference interval(s), 1982: Sept., 661-664

Reference laboratory services, requirements for, 1983: Sept., 509

selection of, 1983: Sept., 507-521

Regan isoenzyme(s), in cancer, 1981: Sept., 481

Registry(ies), of cancer incidence, 1982: Sept., 633

Regulation, congressional, of medical technology, 1981: March, 5-7

executive, of medical technology, 1981: March, 6-7, 9

Reliability, of laboratory information system, 1983: March, 165-177

Renal failure, after transfusion, 1982: March, 225

Report format(s), in anatomic pathology, 1983: March, 140-142

in computerized laboratory, 1983: March, 79-100, 237

in microbiologic computer system, 1983: March, 104-106

interpretive, in computerized laboratory, 1983: March, 205-217

Reporting, interactive, in anatomic pathology, 1983: March, 142-143

interpretive, in clinical laboratory, 1983: March, 205-217

Request for proposal (RFP), for laboratory information system, 1983: March, 9-10, 19-25

Respiratory distress syndrome, adult, fluid therapy in, 1982: March, 39-49

inflammatory response and, 1983: Dec., 601-617

septicemia and, 1983: Dec., 719-744

neonatal, exchange transfusion in, 1981: June, 273

pathogenesis of, 1981: June, 200-202

prenatal diagnosis of, 1981: June, 199-213

Respiratory syncytial virus infection, perinatal, 1981: June, 390-391

Respiratory tract, infection. Also see under etiologic agent, as *Virus*.

invasive diagnostic techniques in, 1982: June, 269-283

laboratory diagnosis of, 1982: June, 259-423

specimens, evaluation of, 1982: June, 259-267

upper, collection and handling of specimens from, 1983: Sept., 533

Resuscitation, of emergency patients, 1982: March, 53-55

Retinol. See *Vitamin A*.

Rh factor, maternal immunization to, in hemolytic disease of newborn, 1982: March, 107-122

Rh hemolytic disease, in neonate, 1981: June, 247  
exchange transfusion in, 1981: June, 265-267

Rh immune globulin, in prevention of Rh immunization, 1982: March, 108-109, 113-119

Rh immunization, in hemolytic disease of newborn, 1982: March, 107-122  
plasma exchange in, 1982: March, 94-95

Rh matching, in emergency cardiovascular surgery, 1982: March, 78-81

Rh system, 1982: March, 142-143

Rh typing, in emergency transfusion, 1982: March, 78-81

Rheumatic disease, drug therapy for, 1981: Sept., 567-573

Riboflavin, antagonist, 1981: Dec., 653  
deficiency, 1981: Dec., 688-690  
laboratory assessment of, 1981: Dec., 685-698

Rickets, vitamin D status and, 1981: Dec., 720-721

Rifampin, toxic effects, 1981: Sept., 595

Rifle. See *Firearm(s); Rifled weapons*.

Rifled weapon(s), entrance wounds from, 1983: June, 264-270  
wounds from, 1983: June, 257-271, 273-294. See also *Firearm wounds*.

Rifling, of gun barrel, 1983: June, 257

Risk-benefit analysis, in test selection, 1982: Dec., 790-791

Rosettes, formation of, 1982: Sept., 580

Rotavirus gastroenteritis, detection by ELISA, 1981: March, 59

Rubella, perinatal, 1981: June, 380-384

Rule of nines, for burn estimation, 1983: June, 301

**SAFETY.** laboratory, federal regulation of, 1983: Sept., 445  
publications for, 1983: Sept., 481

Safety manual, for laboratory, 1983: Sept., 466

Safety regulations, for laboratory, 1983: Sept., 465-482

Salicylate, perinatal effect of, 1981: June, 368  
therapeutic monitoring of, 1981: Sept., 567-573  
toxic effects, 1981: Sept., 570-572

Salicylate saturation index, in bilirubin measurement, 1981: June, 330-332

Schizophrenia, drug therapy for, 1981: Sept., 547-557

Screening, definition of, 1981: March, 24

Screening test(s), for iron deficiency anemia, 1982: Dec., 761-775  
for prostatic cancer, 1982: Dec., 692-695  
mass, for cancer, 1982: Sept., 627-638  
performance characteristics of, 1982:  
Sept., 639-656  
predictive value and, 1982: Dec., 685  
Scurvy, vitamin C status and, 1981: Dec., 675-676

Secretory IgA, in malnutrition, 1981: Dec., 640-641

Security, of laboratory information system, 1983: March, 165-177

Seizure(s), drug therapy for, 1981: Sept., 479-500

Sensitivity of immunologic methods, 1981: March, 61  
of laboratory tests, 1981: March, 8, 11, 27-28  
of screening tests, 1982: Sept., 640-642

Sensitivity analysis, in test evaluation, 1982: Dec., 774-775

Sepsis. See also *Septicemia*.  
burn injury and, 1983: Dec., 801-815  
neonatal, 1981: June, 345-360

Septicemia, lung injury and, 1983: Dec., 719-744

Sequential testing. See *Series testing*.

Series testing, predictive value model in, 1982: Dec., 695-698  
selection of, 1982: Dec., 871-890  
short-term functions of, 1982: Dec., 835-850

Serologic techniques, in blood banking, 1981: March, 73-75  
in chlamydial respiratory infection, 1982: June, 377-379

in fungal respiratory infection, 1982: June, 332-339

in hepatitis, 1982: March, 245  
in *Legionella* infection, 1982: June, 350-356

in perinatal nonbacterial infections, 1981: June, 377-397

in *Pneumocystis* infection, 1982: June, 403-404

in viral respiratory infection, 1982: June, 386-387

preanalytic factors in, 1983: Sept., 535

Serotonin, in anaphylaxis, 1983: Dec., 620  
in endotoxin-induced lung injury, 1983: Dec., 731

Sexually transmitted disease(s), chlamydial, diagnosis of, 1982: June, 371-375

Shewhart criteria, for quality control data, 1983: Sept., 546

Shock, hemorrhagic, fluid management in, 1982: March, 35-63

Shock lung. See *Respiratory distress syndrome, adult*.

Sickle cell disease, erythrocytosis and, 1982: March, 101

Sjögren's syndrome, antibody markers of, 1983: Dec., 754-755

Skeletal injury, in battered child, 1983: June, 332-333

Skeletal remains, determination of identity from, 1983: June, 298

Skin, autoimmune disease of, 1983: Dec., 753-754

- burn injury of. See *Burn(s)*.
- disorders, prostaglandins and, 1983: Dec., 703

Skin tests, in assessment of malnutrition, 1981: Dec., 633-638

Skull injury, from firearms, 1983: June, 267-268, 287-288

- in battered child, 1983: June, 333-334
- in fire victims, 1983: June, 302

SLE. See *Lupus erythematosus, systemic*.

Sleep apnea, vs. asphyxiation, in infants, 1983: June, 338-342

Slow-reacting substance of anaphylaxis (SRS-A), in anaphylaxis, 1983: Dec., 620-625

- in endotoxin-induced lung injury, 1983: Dec., 728
- production of, 1983: Dec., 681

Smoke inhalation; death from, 1983: June, 299-300

Sodium, levels, effect of drugs on, 1981: Dec., 654-655

Sodium meclofenamate. See *Meclofenamate sodium*.

Software, for laboratory information system, 1983: March, 6-7

- for microcomputers (appendix), 1983: March, 59-60
- reliability, in laboratory information system, 1983: March, 170-171
- security, in laboratory information system, 1983: March, 171-173
- selection, in laboratory information system, 1983: March, 27
- in user-designed system, 1983: March, 43-45

Software applications, of microcomputer, in clinical laboratory, 1983: March, 54-59

Software configuration, in laboratory information system, 1983: March, 237

Software maintenance, in laboratory information system, 1983: March, 235

- contract for, 1983: March, 33

Spare parts, for hardware, in laboratory information system, 1983: March, 168

Specificity, of immunologic methods, 1981: March, 60-61

- of laboratory test, 1981: March, 11, 27-28
- of screening tests, 1982: Sept., 640-642

Specimen(s), handling, 1981: Sept., 442

- pathology, automated management of, 1983: March, 139-140

Specimen(s) (*Continued*)

- respiratory, evaluation of, 1982: June, 259-267
- in *Pneumocystis* infection, 1982: June, 396-398
- in recovery of fungi, 1982: June, 323-324
- in viral isolation, 1982: June, 384-386
- transport of, 1982: June, 295-296
- sputum. See *Sputum*.

Spectrophotometry, direct, in bilirubin measurement, 1981: June, 316-318

- in measurement of bilirubin, 1981: June, 330-332
- in measurement of vitamin A, 1981: Dec., 705
- in monitoring acetaminophen, 1981: Sept., 578
- in monitoring salicylate, 1981: Sept., 573
- in monitoring theophylline, 1981: Sept., 566

Spermidine, in malignant disease, 1982: Sept., 507-518

Spermine, in malignant disease, 1982: Sept., 507-518

Spherocyte(s), partial phagocytosis and, 1982: March, 215

Splenectomy, pretransplantation, 1983: Dec., 770

Spondylitis, ankylosing, HLA-B27 antigen and, 1982: March, 130-131

Sputum, specimen, in diagnosis of respiratory infection, 1982: June, 270-271

- in tuberculosis, 1982: June, 311-312
- macroscopic assessment of, 1982: June, 259-260
- microscopic assessment of, 1982: June, 260-262

SRS-A. See *Slow-reacting substance of anaphylaxis*.

Stains and staining. See also specific stains, such as *Gram's stain*.

- acid-fast, in tuberculosis, 1982: June, 311-312
- in albumin dye-binding procedures, 1981: June, 333-336
- in identification of *Chlamydia*, 1982: June, 377
- in identification of *Legionella*, 1982: June, 356-357
- in *Pneumocystis* infection, 1982: June, 396-403

Standard error, of percentage, 1982: Dec., 690

*Staphylococcus aureus* infection, neonatal, 1981: June, 346-348

Stat testing, 1983: Sept., 497-505. See also specific tests.

**Stat testing (Continued)**

- approaches for, 1983: Sept., 498-500
- instrumentation for, 1983: Sept., 501
- setting priorities for, 1983: Sept., 504-505

**Steatorrhea, drug-induced, 1981:** Dec., 648

**Stem cell, collection, therapeutic, 1982:**

- March, 102-103

**Stool cultures, preanalytic factors in, 1983:**

- Sept., 534

**Storage lesion, blood, 1982:** March, 4-6, 22-29

**Streptococcal infection, diagnosis of, 1981:**

- March, 51

**Sudden infant death, vs. asphyxiation, 1983:**

- June, 338-342

**Sulfasalazine, as vitamin antagonist, 1981:**

- Dec., 653

**Sulfonamide(s), toxic effects, 1981:** Sept., 593-594

**Superinfection, laboratory diagnosis, 1981:**

- Sept., 595-596

**Surgery, elective, crossmatch guidelines for, 1982:** March, 172-173

**Susceptibility tests, antimicrobial, in**

- anaerobic respiratory infection, 1982:**
- June, 300-301
- in *Legionella* infection, 1982: June, 363-365
- mycobacterial, 1982: June, 314-315

**Synovial inflammation, prostaglandins and, 1983:** Dec., 702-706

**Syphilis, congenital, 1981:** June, 355-359

**Systemic lupus erythematosus. See *Lupus erythematosus, systemic*.**

**System reliability, in automated clinical laboratory, 1983:** March, 165-177

**T CELL(S). See *Lymphocyte(s)*.**

**Taste, acuity, zinc status and, 1981:** Dec., 755

**Tattooing, around firearm entrance wound, 1983:** June, 266-267

**Technology, computer, in clinical**

- laboratory, symposium on, 1983:**
- March, 3-251. **See also Computer information systems.**
- in laboratory medicine, assessment of, 1981: March, 111-125
- flow-analysis, in leukocyte differential counting, 1981: March, 127-150
- in clinical immunology, assessment of, 1981: March, 77-109
- laboratory, assessment of, 1981: March, 3-19
- symposium on, 1981: March, 1-150
- cost analysis, 1981: March, 4-5, 13-14, 35, 39-47, 118-120

**Technology (Continued)**

- in therapeutic drug monitoring, 1981:
- Sept., 451-466
- medical, assessment of, 1983: March, 186-187
- microbiologic, assessment of, 1981:
- March, 49-65
- of blood banking, 1981: March, 67-76
- of immunoassays, 1981: March, 77-109

**Teeth, determination of identity from, 1983:**

- June, 297-298

**Terminal deoxynucleotidyl transferase (TdT), in leukemia, 1982:** Sept., 484-485

**Test(ing), laboratory. **See also Laboratory test(ing)** and under specific test.**

- preanalytic variables in, 1983:** Sept., 523-538
- "stat," 1983: Sept., 497-505

**Test parameters, in assessing**

- instrumentation needs, 1983:** Sept., 427

**Testis, germ cell tumor of, markers for, 1982:** Sept., 447-453

**Tetracycline, perinatal effect of, 1981:** June, 372

- toxic effects, 1981:** Sept., 589-590

**Theophylline, perinatal effect of, 1981:** June, 372

- therapeutic monitoring of, 1981:** Sept., 559-565
- toxic effects, 1981:** Sept., 565-566

**Therapeutic drug monitoring, 1981:** Sept., 439-597. **See also under specific drugs.**

- chromatographic methods in, 1981:** Sept., 460-463
- confounding factors in, 1981:** Sept., 469-478
- immunoassays in, 1981:** Sept., 453-460
- organization of laboratory service for, 1981:** Sept., 439-450
- pharmacokinetic and pharmacodynamic principles, 1981:** Sept., 467-478
- quality control, 1981:** Sept., 448

**Therapeutic monitoring, in breast cancer, 1982:** Sept., 527-528

- in multiple myeloma, 1982: Sept., 536
- in prostatic cancer, 1982: Sept., 531-532

**Thermal injury. **See Burn injury.****

**Thermistor analysis, in enzyme immunoassay, 1981:** March, 99

**Thin-layer chromatography. **See Chromatography.****

**Thiocyanate, therapeutic monitoring of, 1981:** Sept., 535-536

**Thioridazine, therapeutic monitoring of, 1981:** Sept., 553-554

**Threshold approach, in multiple testing, 1982:** Dec., 871-872

- in therapeutic decision-making, 1981:**
- March, 11, 26, 32-35

**Thrombocyte(s). **See Platelet(s).****

Thrombocytopenia, alloimmune, neonatal, 1981: June, 254-255

Thrombotic thrombocytopenic purpura, plasmapheresis and, 1982: March, 96

Thrombocytopenic purpura, autoimmune, neonatal, 1981: June, 257

Thromboxane(s), in anaphylaxis, 1983: Dec., 622-623

in endotoxin-induced lung injury, 1983: Dec., 724-725

in neutrophil stimulation, 1983: Dec., 786-787

Thymoma, antibody markers of, 1983: Dec., 753

Thyroid, autoimmune disease of, 1983: Dec., 750-752

disorders, test selection in, 1982: Dec., 735-750, 797-798, 803-819

neonatal disorders of, 1981: June, 399-407

Time series analysis, of markers, in monitoring cancer, 1982: Sept., 671-672

Timing, of laboratory tests, to monitor disease, 1982: Dec., 851-870

Tissue immunopathology, symposium on, 1983: Dec., 577-817

Tissue polypeptide antigen (TPA), in breast cancer, 1982: Sept., 547-548

Toxic and biological hazards, 1983: Sept., 472

Toxicity, of acetaminophen, 1981: Sept., 575-577

of antibiotics, 1981: Sept., 587-595

of cephalosporins, 1981: Sept., 589

of digoxin, 1981: Sept., 531

of disopyramide, 1981: Sept., 510-511

of lidocaine, 1981: Sept., 512-513

of lithium, 1981: Sept., 544-545

of nitroprusside, 1981: Sept., 535

of penicillins, 1981: Sept., 588-589

of phenothiazines, 1982: Sept., 555

of phenytoin, 1981: Sept., 514

of procainamide, 1981: Sept., 508-509

of propranolol, 1981: Sept., 515

of quinidine, 1981: Sept., 505-506

of salicylate, 1981: Sept., 570-572

of tetracyclines, 1981: Sept., 589-590

of theophylline, 1981: Sept., 565-566

of trimethoprim, 1981: Sept., 594

of vancomycin, 1981: Sept., 591-592

of vitamin A, 1981: Dec., 703-704

of vitamin C, 1981: Dec., 677

Toxicologic analysis, 1983: June, 367-384, 385-396

in fire deaths, 1983: June, 305-306

in product liability deaths, 1983: June, 400-401

specimens for, 1983: June, 368

Toxicology, forensic, 1983: June, 367-384, 385-396

Toxicology laboratory, 1983: June, 367-384, 385-396

Toxoplasmosis, perinatal, 1981: June, 377-380

Trace evidence, 1983: June, 355-365. See also *Evidence*.

Transferrin, as nutritional index, 1981: Dec., 771

levels, in assessment of iron status, 1981: Dec., 737-739; 1982: Dec., 756-757

Transfusion, blood, in cardiovascular surgery, 1982: Mar., 75-82

in heart surgery, 1982: Mar., 65-85

pretransplantation, 1983: Dec., 770

compatibility testing in, 1982: March, 169-179

exchange, bilirubin levels and, 1981: June, 315

drug therapy and, 1981: June, 277

in neonate, 1981: June, 265-283

hemolytic reactions in, 1982: March, 79, 221-231

in autoimmune hemolytic anemia, 1982: March, 193-210

in hemolytic disease of newborn, 1982: March, 118

massive, 1982: March, 21-34

of blood components, 1981: March, 67-76; 1982: March, 3-19

HLA typing in, 1982: March, 129-130

in neonate, 1981: June, 285-309

partial exchange, in neonate, 1981: June, 277-278

reactions, 1982: March, 78-79, 221-231

transmission of hepatitis and, 1982: March, 233-252

Transplantation, of kidney, HLA typing in, 1982: March, 125-129

of marrow, HLA typing in, 1982: March, 128-129

organ, immunologic principles and, 1983: Dec., 763-778

Transtracheal aspiration (TTA), in anaerobic respiratory infection, 1982: June, 292-293

*Treponema pallidum* infection, neonatal, 1981: June, 355-359

Tricyclic antidepressant(s), therapeutic monitoring of, 1981: Sept., 455, 541-544

Trimethoprim, toxic effects, 1981: Sept., 594

Tuberculosis, laboratory diagnosis of, 1982: June, 305-319

Tuftsin, deficiency, in neutrophil dysfunction, 1983: Dec., 789

Tumor(s), germ cell, markers for, 1982: Sept., 431-458

Tumor marker(s). See also under specific markers, such as *Carcinoembryonic antigen*, or under specific disease.

Tumor marker(s) (*Continued*)  
criteria for clinical utility, 1982: Sept., 511-514  
enzyme, characteristics of, 1982: Sept., 493-494  
in breast cancer, 1982: Sept., 543-565  
assessment of, 1982: Sept., 657-678  
in malignant disease, symposium on, 1982: Sept., 431-678

Turbidimetric assay, 1981: March, 78-79

Type and screen, in pretransfusion testing, 1982: March, 169-179

UNIVERSAL donor blood, 1982: March, 183-184

University of Arizona microbiology system, 1983: March, 107-109

Urinary hormone assay, 1983: Sept., 529

Urine, alcohol levels in, 1983: June, 388, 393  
assays, in *Legionella* infection, 1982: June, 361-362  
cultures, preanalytic factors in, 1983: Sept., 532  
drug levels in, 1983: June, 370-371  
specimens, collection and handling of, 1983: Sept., 532

Urogenital tract, cancer, CK<sub>1</sub> activity in, 1982: Sept., 497-499

Urticular transfusion reactions, 1982: March, 221-227

User design, of laboratory information system, 1983: March, 29, 35-50

VALPROIC acid, therapeutic monitoring of, 1981: Sept., 486-487

Values, changing, coping with, 1983: Sept., 558-560

Vancomycin, toxic effects, 1981: Sept., 591-592

Varicella-zoster virus infection, perinatal, 1981: June, 389-390

Vasopressin deficiency, neonatal, 1981: June, 414-416

Vendor(s), of anatomic pathology software, 1983: March, 143-144  
selection, for laboratory information system, 1983: March, 19-34

Ventricular fibrillation, in electrical injury, 1983: June, 347, 349, 352

Viral infection(s), perinatal, 1981: June, 380-393

Virus, detection by immunologic technique, 1981: March, 52, 55  
in breast cancer, 1982: Sept., 546-547  
respiratory infection, laboratory diagnosis of, 1982: June, 383-391

Vitamin(s), laboratory assessment of, 1981: Dec., 620-621. See also under specific vitamins.  
drug interference, 1981: Dec., 648-651

Vitamin A, deficiency, 1981: Dec., 703-704  
laboratory assessment of, 1981: Dec., 699-711  
drug interference, 1981: Dec., 648-649  
toxicity, 1981: Dec., 703-704

Vitamin antagonists, 1981: Dec., 652-654

Vitamin B<sub>2</sub>. See *Riboflavin*.

Vitamin B<sub>6</sub> antagonists, 1981: Dec., 653  
laboratory assessment of, drug interference, 1981: Dec., 651-652

Vitamin B<sub>12</sub>, antagonist, 1981: Dec., 653  
deficiency, folate status and, 1981: Dec., 782-792  
laboratory assessment of, drug interference, 1981: Dec., 650

Vitamin C, deficiency, 1981: Dec., 676  
drug interactions and, 1981: Dec., 677  
laboratory assessment of, 1981: Dec., 673-684  
drug interference, 1981: Dec., 649-650  
toxicity, 1981: Dec., 677

Vitamin D, deficiency, 1981: Dec., 719-723  
laboratory assessment of, 1981: Dec., 713-727  
drug interference, 1981: Dec., 649-650

Vitamin E, laboratory assessment of, drug interference, 1981: Dec., 649-650

Vitamin K, antagonists, 1981: Dec., 653

Vitreous humor, alcohol levels in, 1983: June, 387-388, 393  
drug levels in, 1983: June, 369

Voice entry devices, in interactive reporting systems, 1983: March, 142-143

Von Gierke's disease, neonatal, 1981: June, 426-427

WASTES, hazardous, disposal of, 1983: Sept., 477-480

Weapons, projectile. See *Firearm(s)*.

White blood cell(s). See *Leukocyte(s)*; *Neutrophil(s)*.

Whole blood, transfusion of, 1982: March, 6-8  
in critically ill, 1982: March, 52

Word processors, 1983: March, 16  
in anatomic pathology, 1983: March, 140-142

Workflow analysis, in clinical laboratory, 1983: March, 11-12, **79-100**, 236  
Work-in-process, in computerized laboratory, 1983: March, 92-98  
Workload analysis, in laboratory, 1983: Sept., 424  
Workload Recording Method, 1983: Sept., 556-562  
Wound(s), firearm. See *Firearm wounds*.  
Wound ballistics, 1983: June, 260-261

## CUMULATIVE INDEX

YELLOW, direct 7, in albumin dye-binding, 1981: June, 335-336  
ZINC, deficiency, 1981: Dec., 745-747  
laboratory assessment of, 1981: Dec., 743-755

